MIME-Version: 1.0
Content-Type: multipart/related; boundary="----=_NextPart_01D92EA1.A6713670"

Данный документ является веб-страницей в одном файле, также называемой файлом веб-архива. Если вы видите это сообщение, значит, данный браузер или редактор не поддерживает файлы веб-архива. Загрузите браузер, поддерживающий веб-архивы, например Windows® Internet Explorer®.

------=_NextPart_01D92EA1.A6713670
Content-Location: file:///C:/680A9711/UA164680101_3D71.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1251"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
1">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 14">
<meta name=3DOriginator content=3D"Microsoft Word 14">
<link rel=3DFile-List href=3D"UA164680101_3D71.files/filelist.xml">
<link rel=3DPreview href=3D"UA164680101_3D71.files/preview.wmf">
<link rel=3DEdit-Time-Data href=3D"UA164680101_3D71.files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>IS</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>Bravada</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>4</o:TotalTime>
  <o:LastPrinted>2017-02-03T09:34:00Z</o:LastPrinted>
  <o:Created>2023-01-22T18:39:00Z</o:Created>
  <o:LastSaved>2023-01-22T18:39:00Z</o:LastSaved>
  <o:Pages>7</o:Pages>
  <o:Words>3147</o:Words>
  <o:Characters>17944</o:Characters>
  <o:Company>SPecialiST RePack</o:Company>
  <o:Lines>149</o:Lines>
  <o:Paragraphs>42</o:Paragraphs>
  <o:CharactersWithSpaces>21049</o:CharactersWithSpaces>
  <o:Version>14.00</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=3DdataStoreItem href=3D"UA164680101_3D71.files/item0001.xml"
target=3D"UA164680101_3D71.files/props002.xml">
<link rel=3DthemeData href=3D"UA164680101_3D71.files/themedata.thmx">
<link rel=3DcolorSchemeMapping
href=3D"UA164680101_3D71.files/colorschememapping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>RU</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:DontUseIndentAsNumberingTabStop/>
   <w:FELineBreak11/>
   <w:WW11IndentRules/>
   <w:DontAutofitConstrainedTables/>
   <w:AutofitLikeWW11/>
   <w:HangulWidthLikeWW11/>
   <w:UseNormalStyleForList/>
   <w:DontVertAlignCellWithSp/>
   <w:DontBreakConstrainedForcedTables/>
   <w:DontVertAlignInTxbx/>
   <w:Word11KerningPairs/>
   <w:CachedColBalance/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val=3D"Cambria Math"/>
   <m:brkBin m:val=3D"before"/>
   <m:brkBinSub m:val=3D"&#45;-"/>
   <m:smallFrac m:val=3D"off"/>
   <m:dispDef/>
   <m:lMargin m:val=3D"0"/>
   <m:rMargin m:val=3D"0"/>
   <m:defJc m:val=3D"centerGroup"/>
   <m:wrapIndent m:val=3D"1440"/>
   <m:intLim m:val=3D"subSup"/>
   <m:naryLim m:val=3D"undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState=3D"false" DefUnhideWhenUsed=3D"true"
  DefSemiHidden=3D"true" DefQFormat=3D"false" DefPriority=3D"99"
  LatentStyleCount=3D"267">
  <w:LsdException Locked=3D"false" Priority=3D"0" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Normal"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"heading 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 7"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 8"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 9"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 7"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 8"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 9"/>
  <w:LsdException Locked=3D"false" Priority=3D"35" QFormat=3D"true" Name=3D=
"caption"/>
  <w:LsdException Locked=3D"false" Priority=3D"10" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" Name=3D"Default Paragraph=
 Font"/>
  <w:LsdException Locked=3D"false" Priority=3D"11" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtitle"/>
  <w:LsdException Locked=3D"false" Priority=3D"22" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Strong"/>
  <w:LsdException Locked=3D"false" Priority=3D"20" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"59" Name=3D"Table Grid"/>
  <w:LsdException Locked=3D"false" UnhideWhenUsed=3D"false" Name=3D"Placeho=
lder Text"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"No Spacing"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" UnhideWhenUsed=3D"false" Name=3D"Revisio=
n"/>
  <w:LsdException Locked=3D"false" Priority=3D"34" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"List Paragraph"/>
  <w:LsdException Locked=3D"false" Priority=3D"29" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"30" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"19" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtle Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"21" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"31" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtle Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"32" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"33" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Book Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"37" Name=3D"Bibliography"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" QFormat=3D"true" Name=3D=
"TOC Heading"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;
	mso-font-charset:204;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1073743103 0 0 415 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:204;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520092929 1073786111 9 0 415 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:204;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520081665 -1073717157 41 0 66047 0;}
@font-face
	{font-family:RimTimes;
	mso-font-alt:"Times New Roman";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:204;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1593833729 1073750107 16 0 415 0;}
@font-face
	{font-family:"Dutch TL";
	mso-font-charset:186;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147482961 1342185546 0 0 159 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:Calibri;
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;}
h2
	{mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Заголовок 2 Знак";
	mso-style-next:Обычный;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	line-height:115%;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:14.0pt;
	font-family:"Cambria","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;
	font-style:italic;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-link:"Текст примечания Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	mso-fareast-language:X-NONE;}
span.MsoCommentReference
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-ansi-font-size:8.0pt;
	mso-bidi-font-size:8.0pt;}
a:link, span.MsoHyperlink
	{mso-style-priority:99;
	mso-style-parent:"";
	color:#0563C1;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-noshow:yes;
	mso-style-priority:99;
	color:purple;
	mso-themecolor:followedhyperlink;
	text-decoration:underline;
	text-underline:single;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"Текст примечания";
	mso-style-link:"Тема примечания Знак";
	mso-style-next:"Текст примечания";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Текст выноски Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:8.0pt;
	font-family:"Tahoma","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:X-NONE;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:Calibri;
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:36.0pt;
	mso-add-space:auto;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:Calibri;
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParag=
raphCxSpFirst
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:Calibri;
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListPar=
agraphCxSpMiddle
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:Calibri;
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagra=
phCxSpLast
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:36.0pt;
	mso-add-space:auto;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:Calibri;
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;}
p.BodyText1, li.BodyText1, div.BodyText1
	{mso-style-name:"Body Text1";
	mso-style-unhide:no;
	mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:21.25pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:RimTimes;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	color:black;
	mso-ansi-language:EN-US;
	mso-fareast-language:LV;}
span.a
	{mso-style-name:"Текст примечания Знак";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Текст примечания";
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
span.a0
	{mso-style-name:"Текст выноски Знак";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Текст выноски";
	mso-ansi-font-size:8.0pt;
	mso-bidi-font-size:8.0pt;
	font-family:"Tahoma","sans-serif";
	mso-ascii-font-family:Tahoma;
	mso-fareast-font-family:Calibri;
	mso-hansi-font-family:Tahoma;
	mso-bidi-font-family:Tahoma;
	mso-ansi-language:UK;}
span.a1
	{mso-style-name:"Тема примечания Знак";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Тема примечания";
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;
	font-weight:bold;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	mso-style-unhide:no;
	mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	mso-layout-grid-align:none;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Verdana","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:Verdana;
	color:black;
	mso-ansi-language:LV;
	mso-fareast-language:EN-US;}
span.2
	{mso-style-name:"Заголовок 2 Знак";
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Заголовок 2";
	mso-ansi-font-size:14.0pt;
	mso-bidi-font-size:14.0pt;
	font-family:"Cambria","serif";
	mso-ascii-font-family:Cambria;
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:Cambria;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;
	font-weight:bold;
	font-style:italic;}
span.a2
	{mso-style-name:"Неразрешенное упоминание";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	color:#605E5C;
	background:#E1DFDD;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	mso-fareast-font-family:Calibri;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:42.5pt 42.5pt 35.45pt 49.65pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 @list l0
	{mso-list-id:228150715;
	mso-list-type:hybrid;
	mso-list-template-ids:-924933040 68747281 68747289 68747291 68747279 68747=
289 68747291 68747279 68747289 68747291;}
@list l0:level1
	{mso-level-text:"%1\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level2
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level3
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l0:level4
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level5
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level6
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l0:level7
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l1
	{mso-list-id:241988552;
	mso-list-type:hybrid;
	mso-list-template-ids:-943295232 69599249 69599257 69599259 69599247 69599=
257 69599259 69599247 69599257 69599259;}
@list l1:level1
	{mso-level-start-at:2;
	mso-level-text:"%1\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level2
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level3
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l1:level4
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level5
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level6
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l1:level7
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l2
	{mso-list-id:268052600;
	mso-list-type:hybrid;
	mso-list-template-ids:2126669414 68747281 68747289 68747291 68747279 68747=
289 68747291 68747279 68747289 68747291;}
@list l2:level1
	{mso-level-text:"%1\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:72.0pt;
	text-indent:-18.0pt;}
@list l2:level2
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:108.0pt;
	text-indent:-18.0pt;}
@list l2:level3
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	margin-left:144.0pt;
	text-indent:-9.0pt;}
@list l2:level4
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:180.0pt;
	text-indent:-18.0pt;}
@list l2:level5
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:216.0pt;
	text-indent:-18.0pt;}
@list l2:level6
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	margin-left:252.0pt;
	text-indent:-9.0pt;}
@list l2:level7
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:288.0pt;
	text-indent:-18.0pt;}
@list l2:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:324.0pt;
	text-indent:-18.0pt;}
@list l2:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	margin-left:360.0pt;
	text-indent:-9.0pt;}
@list l3
	{mso-list-id:400980684;
	mso-list-type:hybrid;
	mso-list-template-ids:1343290256 1036552988 68747289 68747291 68747279 687=
47289 68747291 68747279 68747289 68747291;}
@list l3:level1
	{mso-level-text:"%1\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:54.0pt;
	text-indent:-18.0pt;}
@list l3:level2
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:90.0pt;
	text-indent:-18.0pt;}
@list l3:level3
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	margin-left:126.0pt;
	text-indent:-9.0pt;}
@list l3:level4
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:162.0pt;
	text-indent:-18.0pt;}
@list l3:level5
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:198.0pt;
	text-indent:-18.0pt;}
@list l3:level6
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	margin-left:234.0pt;
	text-indent:-9.0pt;}
@list l3:level7
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:270.0pt;
	text-indent:-18.0pt;}
@list l3:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:306.0pt;
	text-indent:-18.0pt;}
@list l3:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	margin-left:342.0pt;
	text-indent:-9.0pt;}
@list l4
	{mso-list-id:932399944;
	mso-list-type:hybrid;
	mso-list-template-ids:-1799428192 -460952788 69599235 69599237 69599233 69=
599235 69599237 69599233 69599235 69599237;}
@list l4:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:–;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
@list l4:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l4:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l4:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l4:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l4:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l4:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l4:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l4:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l5
	{mso-list-id:1155754713;
	mso-list-type:simple;
	mso-list-template-ids:-1969179664;}
@list l5:level1
	{mso-level-start-at:2;
	mso-level-number-format:roman-upper;
	mso-level-text:"%1\. ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:14.15pt;
	mso-level-legacy-space:0cm;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	mso-ansi-font-size:12.0pt;
	font-family:RimTimes;
	mso-ansi-font-weight:bold;
	mso-ansi-font-style:normal;
	text-decoration:none;
	text-underline:none;}
@list l6
	{mso-list-id:1194920458;
	mso-list-type:hybrid;
	mso-list-template-ids:1564226868 69599249 69599257 69599259 69599247 69599=
257 69599259 69599247 69599257 69599259;}
@list l6:level1
	{mso-level-text:"%1\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6:level2
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6:level3
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l6:level4
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6:level5
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6:level6
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l6:level7
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l7
	{mso-list-id:1416786860;
	mso-list-type:hybrid;
	mso-list-template-ids:81284994 68747281 68747289 68747291 68747279 6874728=
9 68747291 68747279 68747289 68747291;}
@list l7:level1
	{mso-level-text:"%1\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l7:level2
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l7:level3
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l7:level4
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l7:level5
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l7:level6
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l7:level7
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l7:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l7:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l8
	{mso-list-id:1476797930;
	mso-list-type:hybrid;
	mso-list-template-ids:1996144962 -1 69599235 69599237 69599233 69599235 69=
599237 69599233 69599235 69599237;}
@list l8:level1
	{mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l8:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l8:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l8:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l8:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l8:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l8:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l8:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l8:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l9
	{mso-list-id:1522813954;
	mso-list-type:hybrid;
	mso-list-template-ids:1458309228 68747281 68747289 68747291 68747279 68747=
289 68747291 68747279 68747289 68747291;}
@list l9:level1
	{mso-level-text:"%1\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level2
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level3
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l9:level4
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level5
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level6
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l9:level7
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l10
	{mso-list-id:1574119457;
	mso-list-type:hybrid;
	mso-list-template-ids:1539724530 1161207912 -2041419840 69599259 69599247 =
69599257 69599259 69599247 69599257 69599259;}
@list l10:level1
	{mso-level-tab-stop:21.0pt;
	mso-level-number-position:left;
	margin-left:21.0pt;
	text-indent:-18.0pt;}
@list l10:level2
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:57.0pt;
	mso-level-number-position:left;
	margin-left:57.0pt;
	text-indent:-18.0pt;
	font-family:"Dutch TL","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
@list l10:level3
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:93.0pt;
	mso-level-number-position:right;
	margin-left:93.0pt;
	text-indent:-9.0pt;}
@list l10:level4
	{mso-level-tab-stop:129.0pt;
	mso-level-number-position:left;
	margin-left:129.0pt;
	text-indent:-18.0pt;}
@list l10:level5
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:165.0pt;
	mso-level-number-position:left;
	margin-left:165.0pt;
	text-indent:-18.0pt;}
@list l10:level6
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:201.0pt;
	mso-level-number-position:right;
	margin-left:201.0pt;
	text-indent:-9.0pt;}
@list l10:level7
	{mso-level-tab-stop:237.0pt;
	mso-level-number-position:left;
	margin-left:237.0pt;
	text-indent:-18.0pt;}
@list l10:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:273.0pt;
	mso-level-number-position:left;
	margin-left:273.0pt;
	text-indent:-18.0pt;}
@list l10:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:309.0pt;
	mso-level-number-position:right;
	margin-left:309.0pt;
	text-indent:-9.0pt;}
@list l11
	{mso-list-id:1829520064;
	mso-list-type:hybrid;
	mso-list-template-ids:211324736 -460952788 69599235 69599237 69599233 6959=
9235 69599237 69599233 69599235 69599237;}
@list l11:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:–;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
@list l11:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l11:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l11:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l11:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l11:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l11:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l11:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l11:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l12
	{mso-list-id:1889143566;
	mso-list-type:hybrid;
	mso-list-template-ids:-1506741540 -935265568 69337091 69337093 69337089 69=
337091 69337093 69337089 69337091 69337093;}
@list l12:level1
	{mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	color:black;
	mso-ansi-font-weight:bold;
	mso-ansi-font-style:normal;}
@list l12:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l12:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l12:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l12:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l12:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l12:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l12:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l12:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l13
	{mso-list-id:2093351073;
	mso-list-type:hybrid;
	mso-list-template-ids:-1664205988 -935265568 69337091 69337093 69337089 69=
337091 69337093 69337089 69337091 69337093;}
@list l13:level1
	{mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	color:black;
	mso-ansi-font-weight:bold;
	mso-ansi-font-style:normal;}
@list l13:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l13:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l13:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l13:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l13:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l13:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l13:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l13:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Обычная таблица";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext=3D"edit" spidmax=3D"1026"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext=3D"edit">
  <o:idmap v:ext=3D"edit" data=3D"1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=3DRU link=3D"#0563C1" vlink=3Dpurple style=3D'tab-interval:36.0p=
t'>

<div class=3DWordSection1>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal;mso-pagination:none;page-break-after:a=
void;
mso-outline-level:2;mso-layout-grid-align:none;text-autospace:none'><b><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:RU'>ІНСТРУКЦІЯ<o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal;mso-pagination:none;mso-layout-grid-al=
ign:
none;text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span la=
ng=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>для медичного застосування лікарського засобу<o:p>=
</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal;mso-pagination:none;mso-layout-grid-al=
ign:
none;text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span la=
ng=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal;mso-pagination:none;page-break-after:a=
void;
mso-outline-level:1;text-autospace:ideograph-numeric'><b style=3D'mso-bidi-=
font-weight:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-fareast-language:RU'>ТРАМАДОЛ КАЛЦЕКС<o:p></o:p></spa=
n></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal;mso-pagination:none;text-autospace:ide=
ograph-numeric'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>(=
</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-US style=3D'mso-bidi-=
font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-US;
mso-fareast-language:RU'>TRAMADOL</span></b><b style=3D'mso-bidi-font-weigh=
t:
normal'><span lang=3DEN-US style=3D'mso-bidi-font-size:12.0pt;mso-fareast-f=
ont-family:
"Times New Roman";mso-fareast-language:RU'> </span></b><b style=3D'mso-bidi=
-font-weight:
normal'><span lang=3DEN-US style=3D'mso-bidi-font-size:12.0pt;mso-fareast-f=
ont-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:RU'>KALCEKS<=
/span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>)=
<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:11.=
0pt;
mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman";mso-far=
east-language:
RU'><o:p>&nbsp;</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>С=
клад:</span></i></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'><=
o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;punctuation-wrap:simp=
le;
text-autospace:none;vertical-align:baseline'><i style=3D'mso-bidi-font-styl=
e:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-fareast-language:RU'>діюча речовина: </span></i><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:RU'>tramadol;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;punctuation-wrap:simp=
le;
text-autospace:none;vertical-align:baseline'><span lang=3DUK style=3D'mso-b=
idi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU;
mso-bidi-font-weight:bold;mso-bidi-font-style:italic'>2 мл розчину (1 ампул=
а)
містить 100 мг трамадолу гідрохлориду</span><span lang=3DUK style=3D'mso-bi=
di-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>;=
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;punctuation-wrap:simp=
le;
text-autospace:none;vertical-align:baseline'><i style=3D'mso-bidi-font-styl=
e:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-fareast-language:RU'>допоміжні речовини:</span></i><s=
pan
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:RU'> натрію ацетату тригідрат, вода для ін’єкцій.<o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
UK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
UK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>Лікарська форма.</span></b><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'> Розчин для ін’єкцій.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>Основні фізико-хімічні властивості:</span></i><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:RU'> прозора безбарвна рідина.<b style=3D'mso-bidi-fon=
t-weight:
normal'><o:p></o:p></b></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><b style=3D'mso-bidi-font-weight:normal'><span style=3D'font-size:9=
.0pt;
mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman";mso-ans=
i-language:
RU;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><b style=3D'mso-bidi-font-w=
eight:
normal'><span style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"T=
imes New Roman";
mso-ansi-language:RU;mso-fareast-language:RU'>Фармакотерапевтична група.</s=
pan></b><span
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:RU;mso-fareast-language:RU'> </span><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>Аналгетики. Опіоїди. Код АТХ N02A X02.<o:p></o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<b
style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'font-size:10=
.0pt;
mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman";mso-far=
east-language:
RU'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>Ф=
армакологічні
властивості.<o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>Фармакодинаміка.</span></i><span style=3D'mso-bidi=
-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:RU;
mso-fareast-language:RU'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;text-autospace:ideograph-numeric'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK;mso-bidi-font-style:italic'>Трамадол є опіоїдним
знеболювальним засобом центральної дії. Це неселективний чистий агоніст мю-,
дельта- та каппа-рецепторів із більшою афінністю до мю-рецепторів. Інші
механізми забезпечення знеболювальної дії &#8210; інгібування зворотного
захоплення норадреналіну в нейронах і збільшення вивільнення серотоніну.<o:=
p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;text-autospace:ideograph-numeric'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK;mso-bidi-font-style:italic'>Трамадол чинить
протикашльову дію. На відміну від морфіну, у трамадолу в знеболювальних доз=
ах,
навіть у широкому діапазоні, немає пригнічувальної дії на дихання. Також ме=
нший
вплив виявляється на моторику шлунково-кишкового тракту. Дія на серцево-суд=
инну
систему швидше незначна. Повідомлялося, що ефективність трамадолу становить=
 від
1/10 до 1/6 від ефективності морфіну.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;text-autospace:ideograph-numeric'><i><span lang=
=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK'>Фармакокінетика. <o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;text-autospace:ideograph-numeric'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK;mso-bidi-font-weight:bold'>Після внутрішньом’язового
введення у людей трамадол швидко і повністю всмоктується, досягаючи
максимальної концентрації (C<sub>max</sub>) у плазмі крові через 45 хвилин;
біодоступність становить майже 100 %.</span><i><span lang=3DUK style=3D'mso=
-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'><=
o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;text-autospace:ideograph-numeric'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK;mso-bidi-font-weight:bold'>Трамадол володіє високою
афінністю до тканин (V<sub>d</sub>, &#946; =3D 203 ± 40 л). Зв'язок з проте=
їнами
плазми крові &#8210; приблизно 20 %.</span><i><span lang=3DUK style=3D'mso-=
bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'><=
o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;text-autospace:ideograph-numeric'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK;mso-bidi-font-weight:bold'>Трамадол долає
гематоенцефалічний і плацентарний бар'єри. У грудному молоці виявляється ду=
же
незначна кількість трамадолу та його О-дезмет</span><span style=3D'mso-bidi=
-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:RU;
mso-fareast-language:UK;mso-bidi-font-weight:bold'>и</span><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK;mso-bidi-font-weight:bold'>лпохідних (відповідно 0,=
1 %
і 0,02 % від застосованої дози).</span><i><span lang=3DUK style=3D'mso-bidi=
-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'><=
o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;text-autospace:ideograph-numeric'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK;mso-bidi-font-weight:bold'>Інгібування ізоензимів
CYP3A4 і/або CYP2D6, залучених до біотрансформації трамадолу, може впливати=
 на
концентрацію у плазмі крові трамадолу або його активного метаболіту. Дотепер
про клінічно значущу взаємодію не повідомлялось.</span><i><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK'><o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;text-autospace:ideograph-numeric'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK;mso-bidi-font-weight:bold'>Трамадол та його метабол=
іти
майже повністю виводяться нирками. Кумулятивне виведення зі сечею становить=
 90
% від загальної радіоактивності застосованої дози. Напівперіод елімінації t=
<sub>1/2</sub>,
&#946;, незалежно від способу введення, становить приблизно 6 годин. У
пацієнтів <span style=3D'mso-spacerun:yes'> </span>віком від 75 років він м=
оже
збільшитися приблизно в 1,4 раза. У пацієнтів із цирозом печінки напівперіод
елімінації становив 13,3 ± 4,9 години у трамадолу та 18,5 ± 9,4 години у
О-дезамінотрамадолу, у виняткових випадках &#8210; відповідно 22,3 години і=
 36
годин. У пацієнтів з нирковою недостатністю (кліренс креатиніну &lt; 5 мл/х=
в) ці
показники становили відповідно 11 ± 3,2 години та 16,9 ± 3 години, у винятк=
ових
випадках &#8210; відповідно 19,5 години і 43,2 години.</span><i><span lang=
=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK'><o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;text-autospace:ideograph-numeric'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK;mso-bidi-font-weight:bold'>В організмі людини трама=
дол
метаболізується в основному шляхом N- та О-деметилування, а також шляхом
кон'югації продуктів О-деметилування з глюкуроновою кислотою. Фармакологічно
активним є тільки О-дезметилтрамадол. Серед інших метаболітів у кількісному
відношенні існують значні індивідуальні відмінності. Дотепер у сечі визнача=
ють
11 метаболітів. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;text-autospace:ideograph-numeric'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK;mso-bidi-font-weight:bold'>У діапазоні терапевтичних
доз трамадол володіє лінійним фармакокінетичним профілем. Зв'язок концентра=
ції у
плазмі крові зі знеболювальним ефектом залежить від дози, однак в окремих
випадках &#8210; з великим відхиленням. Концентрація у плазмі крові 100-300=
 нг/мл
зазвичай є ефективною.</span><i><span lang=3DUK style=3D'mso-bidi-font-size=
:12.0pt;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'><o:p></o=
:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<span
lang=3DUK style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt;mso-fareast-f=
ont-family:
"Times New Roman";mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<b
style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>К=
лінічні
характеристики.<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>П=
оказання.<o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span style=3D'mso-bidi-font-size:12.0pt;mso-fa=
reast-font-family:
"Times New Roman";mso-ansi-language:RU;mso-fareast-language:UK'>Для зменшен=
ня
помірного та сильного болю.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<span
style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt;mso-fareast-font-family=
:"Times New Roman";
mso-ansi-language:RU;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>П=
ротипоказання</span></i></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>.=
</span></b><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:RU'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;text-autospace:none'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>Підвищена чутливість до трамадолу гідрохлориду або=
 до
інших компонентів препарату.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;text-autospace:none'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>Гостре отруєння алкоголем, снодійними препаратами,
знеболювальними засобами, </span><span lang=3DUK style=3D'mso-bidi-font-siz=
e:12.0pt;
mso-fareast-language:UK'>опіоїдними або іншими психотропними препаратами</s=
pan><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;text-autospace:none'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>Одночасне застосування інгібіторів моноаміноксидази
(МАО) або період їх застосування останні 14 днів.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;text-autospace:none'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>Е</span><span lang=3DUK style=3D'mso-bidi-font-siz=
e:12.0pt;
mso-fareast-language:UK'>пілепсія, що не контролюється лікуванням</span><sp=
an
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;text-autospace:none'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>Під час терапії припинення вживання наркотиків.</s=
pan><span
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:RU;mso-fareast-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;text-autospace:none'><span
style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt;mso-fareast-font-family=
:"Times New Roman";
mso-ansi-language:RU;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;text-autospace:none'><b
style=3D'mso-bidi-font-weight:normal'><i style=3D'mso-bidi-font-style:norma=
l'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:RU'>Взаємодія з іншими лікарськими засобами та інші ви=
ди
взаємодій.</span></i></b><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:UK;mso-bidi-font-weight:bold'>Лікарс=
ький
засіб Трамадол Калцекс не можна застосовувати разом з інгібіторами МАО (див=
. </span><span
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:RU;mso-fareast-language:UK;mso-bidi-font-weight:bold'>р</=
span><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold'>озділ «Протипоказання»).=
 У
пацієнтів, які отримували лікування інгібіторами МАО протягом 14 днів до
початку застосування опіоїду петидину, спостерігалася небезпечна для життя
взаємодія, яка зачіпає центральну нервову систему (ЦНС), дихальну і серцеву
функції та функцію кровообігу. Аналогічн</span><span style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:RU;
mso-fareast-language:UK;mso-bidi-font-weight:bold'>у</span><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK;mso-bidi-font-weight:bold'> взаємоді</span><span
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:RU;mso-fareast-language:UK;mso-bidi-font-weight:bold'>ю</=
span><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold'> з інгібіторами МАО не м=
ожна
виключати і в разі застосування трамадолу.</span><span style=3D'mso-bidi-fo=
nt-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:RU;
mso-fareast-language:UK;mso-bidi-font-weight:bold'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:UK;mso-bidi-font-weight:bold'>При
одночасному або попередньому застосуванні циметидину (інгібітор ферментів) =
</span><span
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:RU;mso-fareast-language:UK;mso-bidi-font-weight:bold'>у</=
span><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold'> зв'язку з отриманими
фармакок</span><span style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:RU;mso-fareast-language:UK;mso-bidi-fon=
t-weight:
bold'>і</span><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareas=
t-font-family:
"Times New Roman";mso-fareast-language:UK;mso-bidi-font-weight:bold'>нети</=
span><span
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:RU;mso-fareast-language:UK;mso-bidi-font-weight:bold'>чни=
</span><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold'>ми результатами клінічно
значуща взаємодія не очікується.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:UK;mso-bidi-font-weight:bold'>При
одночасному або попередньому застосуванні карбамазепіну (індуктор ферментів)
може зменшитися знеболювальний ефект і скоротитися час його дії.<o:p></o:p>=
</span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:UK;mso-bidi-font-weight:bold'>Одноча=
сне
застосування лікарського засобу Трамадол Калцекс та інших препаратів, що
пригнічують ЦНС, в тому числі вживання алкоголю, може посилити вплив на ЦНС=
.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:UK;mso-bidi-font-weight:bold'>Трамад=
ол
може спричиняти судоми і посилити вплив селективних інгібіторів зворотного
захоплення серотоніну (СІЗЗС), інгібіторів зворотного захоплення серотоніну
норадреналіну (ІЗЗСН), трициклічних антидепресантів, антипсихотичних засобі=
в та
інших препаратів, що знижують судомний поріг (наприклад, бупропіону,
міртазапіну, тетрагідроканнабінолу), спричиняючи судоми. Одночасне терапевт=
ичне
застосування трамадолу та серотонінергічних засобів, наприклад СІЗЗС,
інгібіторів зворотного захоплення серотоніну-норепінефрину, інгібіторів МАО
(див. розділ «Протипоказання»), трициклічних антидепресантів і міртазапіну =
може
спричинити серотоніновий синдром – потенційно небезпечний для життя стан<sp=
an
style=3D'mso-spacerun:yes'>  </span>(див. розділи «Особливості застосування=
» та
«Побічні реакції»).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:UK;mso-bidi-font-weight:bold'>При
одночасному застосуванні трамадолу та похідних кумарину (наприклад, варфари=
ну)
слід дотримуватися обережності, оскільки повідомлялося про підвищене міжнар=
одне
нормалізоване відношення (МНВ) з вираженою кровотечею та екхімозом у деяких
пацієнтів.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:UK;mso-bidi-font-weight:bold'>Інші
активні речовини, що пригнічують CYP3A4, наприклад кетоконазол і еритроміци=
н,
можуть затримувати метаболізм трамадолу (N-деметилювання) і, можливо,
метаболізм активного<span style=3D'mso-spacerun:yes'>         
</span>О-деметильованого метаболіту. Клінічне значення цієї взаємодії не
вивчено.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:UK;mso-bidi-font-weight:bold'>Застос=
ування
у небагатьох дослідженнях протиблювальних засобів </span><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-language:UK;mso-bidi-font-we=
ight:
bold'>с</span><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareas=
t-language:
UK'>елективних антагоністів 5НТз серотонінових рецепторів (<span
style=3D'mso-bidi-font-weight:bold'>ондансетрону) </span></span><span lang=
=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK;mso-bidi-font-weight:bold'>до або після операції зб=
ільшує
потребу в трамадолі у пацієнтів з післяопераційними болями.<o:p></o:p></spa=
n></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:10.0pt;mso-bidi-fon=
t-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK;
mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>О=
собливості
застосування.</span></i></b><span lang=3DUK style=3D'mso-bidi-font-size:12.=
0pt;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold;mso-bidi-font-style:itali=
c'>При
наявності опіатної залежності, травми голови, шоку, порушень свідомості нез=
розумілого
походження, порушень дихального центру та дихальної функції або підвищеного
внутрішньочерепного тиску лікарський засіб Трамадол Калцекс можна застосову=
вати
тільки при дотриманні особливої обережності.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold;mso-bidi-font-style:itali=
c'>Лікування
пацієнтів із пригніченням дихання або при одночасному застосуванні депресан=
тів
ЦНС (див. розділ «Взаємодія з іншими лікарськими засобами та інші види
взаємодій»), або при значному перевищенні рекомендованої максимальної добов=
ої
дози слід проводити з обережністю, оскільки в таких ситуаціях не можна
виключати можливість пригнічення дихання.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold;mso-bidi-font-style:itali=
c'>Спостерігалися
судоми при застосуванні трамадолу в рекомендованих дозах. Ризик може
підвищитися, якщо доза трамадолу перевищує рекомендовану денну дозу (400 мг=
).
Трамадол може збільшити ризик виникнення судомних нападів при одночасному
застосуванні препаратів, що знижують судомний поріг (див. розділ «Взаємодія=
 з
іншими лікарськими засобами та інші види взаємодій»). Пацієнтам з епілепсією
або схильністю до судомних нападів трамадол можна застосовувати тільки в ра=
зі
крайньої необхідності.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK;
mso-bidi-font-weight:bold'>Серотоніновий синдром<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold;mso-bidi-font-style:itali=
c'>Повідомлялося
про розвиток серотонінового синдрому, потенційно небезпечного для життя, у =
пацієнтів,
які приймали трамадол у комбінації з іншими серотонінергічними засобами або
тільки трамадол</span><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:LV;mso-fareast-=
language:
UK;mso-bidi-font-weight:bold;mso-bidi-font-style:italic'> </span><span lang=
=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK;mso-bidi-font-weight:bold;mso-bidi-font-style:itali=
c'>(див.
розділи «Взаємодія з іншими лікарськими засобами та інші види взаємодій», «=
Передозування»
та «Побічні реакції»).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold;mso-bidi-font-style:itali=
c'>Якщо
супутнє лікування іншими серотонінергічними засобами є клінічно виправданим,
рекомендується ретельне спостереження за пацієнтом, особливо на початку
лікування та під час підвищення дози.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold;mso-bidi-font-style:itali=
c'>Симптоми
серотонінового синдрому можуть включати зміни психічного стану, вегетативну
нестабільність, нервово-м’язові аномалії та/або шлунково-кишкові симптоми.<=
o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold;mso-bidi-font-style:itali=
c'>При
підозрі на серотоніновий синдром слід розглянути можливість зменшення дози =
або
припинення терапії залежно від тяжкості симптомів. Відміна серотонінергічних
препаратів зазвичай призводить до швидкого поліпшення стану.<o:p></o:p></sp=
an></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK;mso-bidi-=
font-weight:
bold'>Надниркова недостатність<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:UK;mso-bidi-font-weight:bold'>Опіоїд=
ні
аналгетики можуть призвести до оборотної наднирково-залозної недостатності,=
 що
вимагає контролю і замісної терапії глюкокортикоїдами.</span><span lang=3DU=
K> </span><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold'>Симптомами
наднирково-залозної недостатності є, наприклад,</span><span lang=3DUK> </sp=
an><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold'>сильний біль у животі,
нудота, блювання,</span><span lang=3DUK> </span><span lang=3DUK style=3D'ms=
o-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK;
mso-bidi-font-weight:bold'>низький артеріальний тиск, сильна втома, зниження
апетиту та втрата маси тіла.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK;
mso-bidi-font-weight:bold'>Порушення дихання, пов’язані зі сном<o:p></o:p><=
/span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold;mso-bidi-font-style:itali=
c'>Опіоїди
можуть спричинити порушення дихання, пов’язані зі сном, включаючи центральне
апное сну (ЦАС) та гіпоксемію, пов’язану зі сном. Вживання опіоїдів збільшує
ризик ЦАС залежно від дози. Для пацієнтів, які мають ЦАС, потрібно врахувати
зменшення загальної дози опіоїдів.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold;mso-bidi-font-style:itali=
c'>Трамадол
володіє низьким потенціалом виникнення залежності. У разі тривалого застосу=
вання
може розвинутися звикання, психічна та фізична залежність. Тому пацієнтам зі
схильністю до зловживання лікарськими засобами або схильністю до залежності=
 від
них лікування трамадолом слід проводити тільки на короткий час і під суворим
медичним наглядом.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold;mso-bidi-font-style:itali=
c'>Цей
препарат не призначений як засіб замісної терапії при опіатній залежності.
Незважаючи на те, що трамадол є опіатним агоністом, він не може зменшити
симптоми відміни морфію.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold;mso-bidi-font-style:itali=
c'>Під
час застосування лікарського засобу Трамадол Калцекс не слід вживати алкого=
ль.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold;mso-bidi-font-style:itali=
c'>Розчин
для ін'єкцій Трамадол Калцекс містить менше 1 ммоль (23 мг) натрію в 1 ампу=
лі.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:10.=
0pt;
mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman";mso-far=
east-language:
RU'><o:p>&nbsp;</o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>З=
астосування
у період вагітності або годування груддю.</span></i><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK;mso-bidi-=
font-weight:
bold'>Вагітність.</span></i><span lang=3DUK style=3D'mso-bidi-font-size:12.=
0pt;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK;mso-bidi-=
font-weight:
bold;mso-bidi-font-style:italic'> Трамадол долає плацентарний бар'єр. Доста=
тніх
доказів безпеки трамадолу в період вагітності у людини немає, тому трамадол=
 не
можна застосовувати вагітним.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:UK;mso-bidi-font-weight:bold;mso-bid=
i-font-style:
italic'>Застосування трамадолу до або під час пологів не впливає на
скоротливість матки. У новонароджених це може спричинити зміни частоти диха=
ння,
які зазвичай клінічно незначущі. Тривале застосування у період вагітності м=
оже спричинити
симптоми відміни препарату у новонародженого.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK;mso-bidi-=
font-weight:
bold'>Період годування груддю.</span></i><span lang=3DUK style=3D'mso-bidi-=
font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK;
mso-bidi-font-weight:bold;mso-bidi-font-style:italic'> Приблизно 0,1 % від
застосовуваної матір'ю дози проникає у материнське молоко. У період годуван=
ня
груддю застосування трамадолу не рекомендується. Після застосування однораз=
ової
дози трамадолу зазвичай немає необхідності переривати грудне годування дити=
ни.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:UK;mso-bidi-font-weight:bold'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>Здатність впливати на швидкість реакції при керува=
нні
автотранспортом або іншими механізмами.<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:RU'>Навіть при застосуванні відповід=
но
до вказівок трамадол може спричинити сонливість і запаморочення, таким чино=
м,
може послабити здатність реагування й управління транспортними засобами та
обслуговування механізмів. Особливо це стосується впливу у комбінації з
алкоголем та іншими психотропними речовинами.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span style=3D'font-size:8.0pt;mso-bid=
i-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:RU;
mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>С=
посіб
застосування та дози.</span></i></b><i style=3D'mso-bidi-font-style:normal'=
><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:RU'><o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:ideogr=
aph-numeric'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>Застосовувати внутрішньовенно, внутрішньом'язово а=
бо
підшкірно.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:ideogr=
aph-numeric'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>Дозу потрібно підбирати залежно від інтенсивності =
болю
та індивідуальної чутливості пацієнта. Завжди слід застосовувати найменшу
ефективну знеболювальну дозу. Загальна добова доза трамадолу не повинна
перевищувати 400 мг (відповідає 8 мл розчину для ін'єкцій Трамадолу Калцекс=
). У
виняткових випадках, при клінічній необхідності, лікар може призначити більш
високу денну дозу.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:ideogr=
aph-numeric'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>Якщо лікар не призначив інакше, лікарський засіб Т=
рамадол
Калцекс слід застосовувати в такий спосіб:<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:ideogr=
aph-numeric'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>Д=
орослим
і дітям віком від 12 років:</span></i><span lang=3DUK style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'> =
залежно
від інтенсивності болю застосовувати 50-100 мг трамадолу (відповідає 1-2 мл
розчину для ін'єкцій Трамадол Калцекс) через кожні 4-6 годин. Не рекомендує=
ться
перевищувати максимальну денну дозу 400 мг (4 ампули).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:ideogr=
aph-numeric'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>Д=
ітям
віком від 1 до 12 років:</span></i><span lang=3DUK style=3D'mso-bidi-font-s=
ize:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'> =
одноразова
доза трамадолу становить 1-2 мг/кг маси тіла. Зазвичай застосовують найменшу
ефективну знеболювальну дозу. Денна доза не повинна перевищувати найменшу з=
 цих
доз &#8210; 8 мг/кг маси тіла або 400 мг активної речовини.<o:p></o:p></spa=
n></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:ideogr=
aph-numeric'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>Розчин для ін'єкцій Трамадол Калцекс не рекомендує=
ться
дітям віком до 1 року.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:ideogr=
aph-numeric'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>П=
ацієнти
літнього віку<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:ideogr=
aph-numeric'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>Пацієнтам віком до 75 років, у яких клінічно не вс=
тановлена
печінкова або ниркова недостатність, коригування доз зазвичай не потрібно. У
пацієнтів віком від 75 років можливе уповільнене виведення препарату, тому,=
 при
необхідності, інтервали між дозами слід збільшувати індивідуально.<o:p></o:=
p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:ideogr=
aph-numeric'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>Н=
иркова
недостатність/діаліз та порушення діяльності печінки<o:p></o:p></span></i><=
/p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:ideogr=
aph-numeric'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>У пацієнтів з нирковою та/або печінковою недостатн=
істю
виведення трамадолу загальмовано. Рекомендується ретельно зважити необхідні=
сть
збільшення інтервалу між дозами для таких пацієнтів.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:ideogr=
aph-numeric'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>С=
посіб
застосування<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:ideogr=
aph-numeric'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>Внутрішньовенно (розчин для ін'єкцій слід вводити
повільно (1 мл (50 мг трамадолу гідрохлориду) на хвилину)), внутрішньом'язо=
во
або підшкірно. Лікарський засіб Трамадол Калцекс можна також розбавляти
розчином для інфузій (наприклад, 0,9 % розчином натрію хлориду або 5 % розч=
ином
глюкози) і вводити у вигляді інфузії.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:ideogr=
aph-numeric'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>Розрахунок обсягу ін'єкції:<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:ideogr=
aph-numeric'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>Розрахувати повну дозу необхідного трамадолу
гідрохлориду (мг): маса тіла (кг) х доза (мг/кг). Розрахувати обсяг введено=
го
розведеного розчину (мл): повну дозу (мг) розділити на відповідну концентра=
цію
розведеного розчину (мг/мл, див. таблицю нижче).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:ideogr=
aph-numeric'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>Розведення розчину для ін'єкцій Трамадол Калцекс:<=
o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:ideogr=
aph-numeric'><span
lang=3DUK style=3D'font-size:8.0pt;mso-bidi-font-size:12.0pt;mso-fareast-fo=
nt-family:
"Times New Roman";mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></p>

<div align=3Dcenter>

<table class=3DMsoNormalTable border=3D1 cellspacing=3D0 cellpadding=3D0
 style=3D'margin-left:-97.65pt;border-collapse:collapse;border:none;mso-bor=
der-alt:
 solid windowtext .5pt;mso-yfti-tbllook:480;mso-padding-alt:0cm 5.4pt 0cm 5=
.4pt;
 mso-border-insideh:.5pt solid windowtext;mso-border-insidev:.5pt solid win=
dowtext'>
 <tr style=3D'mso-yfti-irow:0;mso-yfti-firstrow:yes'>
  <td width=3D303 valign=3Dtop style=3D'width:227.4pt;border:solid windowte=
xt 1.0pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
  "Times New Roman";mso-fareast-language:UK'>Концентрація розведеного розчи=
ну
  (трамадолу гідрохлорид<span style=3D'mso-spacerun:yes'>  </span>мг/мл)<o:=
p></o:p></span></p>
  </td>
  <td width=3D331 valign=3Dtop style=3D'width:248.5pt;border:solid windowte=
xt 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
  "Times New Roman";mso-fareast-language:UK'>Трамадол Калцекс, 50 мг/мл роз=
чин
  для ін’єкцій (2 мл ампула) + доданий розчинник)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:1'>
  <td width=3D303 valign=3Dtop style=3D'width:227.4pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
  "Times New Roman";mso-fareast-language:UK'>25, 0 мг/мл<o:p></o:p></span><=
/p>
  </td>
  <td width=3D331 valign=3Dtop style=3D'width:248.5pt;border-top:none;borde=
r-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span style=3D'mso-bidi-font-size:12.0pt;mso-fareast-f=
ont-family:
  "Times New Roman";mso-ansi-language:RU;mso-bidi-font-weight:bold'>2&nbsp;=
мл +
  2&nbsp;мл</span><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fa=
reast-font-family:
  "Times New Roman";mso-fareast-language:UK'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:2'>
  <td width=3D303 valign=3Dtop style=3D'width:227.4pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
  "Times New Roman";mso-fareast-language:UK'>16,7 мг/ мл<o:p></o:p></span><=
/p>
  </td>
  <td width=3D331 valign=3Dtop style=3D'width:248.5pt;border-top:none;borde=
r-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span style=3D'mso-bidi-font-size:12.0pt;mso-fareast-f=
ont-family:
  "Times New Roman";mso-ansi-language:RU;mso-bidi-font-weight:bold'>2&nbsp;=
мл +
  4&nbsp;мл</span><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fa=
reast-font-family:
  "Times New Roman";mso-fareast-language:UK'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:3'>
  <td width=3D303 valign=3Dtop style=3D'width:227.4pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
  "Times New Roman";mso-fareast-language:UK'>12,5 мг/мл<o:p></o:p></span></=
p>
  </td>
  <td width=3D331 valign=3Dtop style=3D'width:248.5pt;border-top:none;borde=
r-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span style=3D'mso-bidi-font-size:12.0pt;mso-fareast-f=
ont-family:
  "Times New Roman";mso-ansi-language:RU;mso-bidi-font-weight:bold'>2&nbsp;=
мл +
  6&nbsp;мл</span><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fa=
reast-font-family:
  "Times New Roman";mso-fareast-language:UK'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:4'>
  <td width=3D303 valign=3Dtop style=3D'width:227.4pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
  "Times New Roman";mso-fareast-language:UK'>10,0 мг/мл<o:p></o:p></span></=
p>
  </td>
  <td width=3D331 valign=3Dtop style=3D'width:248.5pt;border-top:none;borde=
r-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span style=3D'mso-bidi-font-size:12.0pt;mso-fareast-f=
ont-family:
  "Times New Roman";mso-ansi-language:RU;mso-bidi-font-weight:bold'>2&nbsp;=
мл +
  8&nbsp;мл</span><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fa=
reast-font-family:
  "Times New Roman";mso-fareast-language:UK'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:5'>
  <td width=3D303 valign=3Dtop style=3D'width:227.4pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
  "Times New Roman";mso-fareast-language:UK'>8,3 мг/мл<o:p></o:p></span></p>
  </td>
  <td width=3D331 valign=3Dtop style=3D'width:248.5pt;border-top:none;borde=
r-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span style=3D'mso-bidi-font-size:12.0pt;mso-fareast-f=
ont-family:
  "Times New Roman";mso-ansi-language:RU;mso-bidi-font-weight:bold'>2&nbsp;=
мл +
  10&nbsp;мл</span><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-f=
areast-font-family:
  "Times New Roman";mso-fareast-language:UK'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:6'>
  <td width=3D303 valign=3Dtop style=3D'width:227.4pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
  "Times New Roman";mso-fareast-language:UK'>7,1 мг/мл<o:p></o:p></span></p>
  </td>
  <td width=3D331 valign=3Dtop style=3D'width:248.5pt;border-top:none;borde=
r-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span style=3D'mso-bidi-font-size:12.0pt;mso-fareast-f=
ont-family:
  "Times New Roman";mso-ansi-language:RU;mso-bidi-font-weight:bold'>2&nbsp;=
мл +
  12&nbsp;мл</span><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-f=
areast-font-family:
  "Times New Roman";mso-fareast-language:UK'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:7'>
  <td width=3D303 valign=3Dtop style=3D'width:227.4pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
  "Times New Roman";mso-fareast-language:UK'>6,3 мг/мл<o:p></o:p></span></p>
  </td>
  <td width=3D331 valign=3Dtop style=3D'width:248.5pt;border-top:none;borde=
r-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span style=3D'mso-bidi-font-size:12.0pt;mso-fareast-f=
ont-family:
  "Times New Roman";mso-ansi-language:RU;mso-bidi-font-weight:bold'>2&nbsp;=
мл +
  14&nbsp;мл</span><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-f=
areast-font-family:
  "Times New Roman";mso-fareast-language:UK'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:8'>
  <td width=3D303 valign=3Dtop style=3D'width:227.4pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
  "Times New Roman";mso-fareast-language:UK'>5,6 мг/мл<o:p></o:p></span></p>
  </td>
  <td width=3D331 valign=3Dtop style=3D'width:248.5pt;border-top:none;borde=
r-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span style=3D'mso-bidi-font-size:12.0pt;mso-fareast-f=
ont-family:
  "Times New Roman";mso-ansi-language:RU;mso-bidi-font-weight:bold'>2&nbsp;=
мл +
  16&nbsp;мл</span><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-f=
areast-font-family:
  "Times New Roman";mso-fareast-language:UK'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:9;mso-yfti-lastrow:yes'>
  <td width=3D303 valign=3Dtop style=3D'width:227.4pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
  "Times New Roman";mso-fareast-language:UK'>5,0 мг/мл<o:p></o:p></span></p>
  </td>
  <td width=3D331 valign=3Dtop style=3D'width:248.5pt;border-top:none;borde=
r-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-bot=
tom:.0001pt;
  text-align:center;line-height:normal;mso-layout-grid-align:none;text-auto=
space:
  ideograph-numeric'><span style=3D'mso-bidi-font-size:12.0pt;mso-fareast-f=
ont-family:
  "Times New Roman";mso-ansi-language:RU;mso-bidi-font-weight:bold'>2&nbsp;=
мл +
  18&nbsp;мл</span><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-f=
areast-font-family:
  "Times New Roman";mso-fareast-language:UK'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

</div>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:ideogr=
aph-numeric'><span
lang=3DUK style=3D'font-size:3.0pt;mso-bidi-font-size:12.0pt;mso-fareast-fo=
nt-family:
"Times New Roman";mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:UK'>Відповідно до розрахунків, розве=
сти
вміст ампули Трамадол Калцекс, додаючи відповідний розчинник, розмішати і в=
вести
отриманий обсяг розведеного розчину.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK'>Тривалість застосування<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:UK'>Трамадол ні за яких обставин не
можна застосовувати довше, ніж це необхідно. Якщо, приймаючи до уваги харак=
тер
і тяжкість захворювання, необхідно тривале знеболювальне лікування трамадол=
ом,
то необхідно ретельно і регулярно контролювати стан пацієнта (при необхідно=
сті
припиняючи лікування) для визначення необхідності та режиму дозування
подальшого лікування.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><u><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>Як відкр=
ити
ампулу:<o:p></o:p></span></u></p>

<p class=3DMsoListParagraphCxSpFirst style=3D'margin-top:0cm;margin-right:0=
cm;
margin-bottom:0cm;margin-left:14.2pt;margin-bottom:.0001pt;mso-add-space:au=
to;
text-align:justify;text-indent:-14.2pt;line-height:normal;mso-list:l3 level=
1 lfo14'><![if !supportLists]><span
style=3D'mso-fareast-font-family:"Times New Roman";mso-ansi-language:RU'><s=
pan
style=3D'mso-list:Ignore'>1)<span style=3D'font:7.0pt "Times New Roman"'>&n=
bsp;&nbsp;
</span></span></span><![endif]><span style=3D'mso-ansi-language:RU'>Поверну=
ти
ампулу кольоровою точкою до себе. Злегка постукати пальцем по верхній части=
ні
ампули, щоб розчин спустився в нижню частину ампули.<o:p></o:p></span></p>

<p class=3DMsoListParagraphCxSpLast style=3D'margin-top:0cm;margin-right:0c=
m;
margin-bottom:0cm;margin-left:14.2pt;margin-bottom:.0001pt;mso-add-space:au=
to;
text-align:justify;text-indent:-14.2pt;line-height:normal;mso-list:l3 level=
1 lfo14'><![if !supportLists]><span
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:RU;mso-fareast-language:RU'><span style=3D'mso-list:Ignor=
e'>2)<span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><!=
[endif]><span
style=3D'mso-ansi-language:RU'>Ампулу відкривати обома руками: утримуючи ни=
жню
частину ампули в одній руці, іншою рукою <span
style=3D'mso-spacerun:yes'> </span>натиснути на верхню частину ампули в нап=
рямку
від кольорової точки (див. рисунок нижче).</span><span style=3D'mso-bidi-fo=
nt-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:RU;
mso-fareast-language:RU'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span style=3D'mso-ansi-language:RU;mso-fareast-langua=
ge:
RU;mso-no-proof:yes'><!--[if gte vml 1]><v:shapetype id=3D"_x0000_t75"
 coordsize=3D"21600,21600" o:spt=3D"75" o:preferrelative=3D"t" path=3D"m@4@=
5l@4@11@9@11@9@5xe"
 filled=3D"f" stroked=3D"f">
 <v:stroke joinstyle=3D"miter"/>
 <v:formulas>
  <v:f eqn=3D"if lineDrawn pixelLineWidth 0"/>
  <v:f eqn=3D"sum @0 1 0"/>
  <v:f eqn=3D"sum 0 0 @1"/>
  <v:f eqn=3D"prod @2 1 2"/>
  <v:f eqn=3D"prod @3 21600 pixelWidth"/>
  <v:f eqn=3D"prod @3 21600 pixelHeight"/>
  <v:f eqn=3D"sum @0 0 1"/>
  <v:f eqn=3D"prod @6 1 2"/>
  <v:f eqn=3D"prod @7 21600 pixelWidth"/>
  <v:f eqn=3D"sum @8 21600 0"/>
  <v:f eqn=3D"prod @7 21600 pixelHeight"/>
  <v:f eqn=3D"sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok=3D"f" gradientshapeok=3D"t" o:connecttype=3D"rect"/>
 <o:lock v:ext=3D"edit" aspectratio=3D"t"/>
</v:shapetype><v:shape id=3D"Picture_x0020_2" o:spid=3D"_x0000_i1025" type=
=3D"#_x0000_t75"
 style=3D'width:289.5pt;height:136.5pt;visibility:visible'>
 <v:imagedata src=3D"UA164680101_3D71.files/image001.png" o:title=3D""/>
</v:shape><![endif]--><![if !vml]><img width=3D386 height=3D182
src=3D"UA164680101_3D71.files/image002.jpg" v:shapes=3D"Picture_x0020_2"><!=
[endif]></span><b
style=3D'mso-bidi-font-weight:normal'><i style=3D'mso-bidi-font-style:norma=
l'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'><o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:5.0=
pt;
mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman";mso-far=
east-language:
UK'><o:p>&nbsp;</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK'>Діти</span></i><i style=3D'mso-bidi-font-style:nor=
mal'><span
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:RU;mso-fareast-language:UK'>.</span></i><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;text-autospace:ideograph-numeric'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:UK;mso-bidi-font-weight:bold;mso-bidi-font-style:itali=
c'>Не
застосовувати дітям віком до 1 року.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:7.0pt;mso-bi=
di-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'><=
o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>П=
ередозування.</span></i></b><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:RU'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.=
0pt;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK;mso-bidi-=
font-weight:
bold'>У разі передозування трамадолу очікуються в основному такі ж симптоми=
, як
і в разі передозування інших знеболювальних препаратів центральної дії
(опіоїдів). В основному цими симптомами є міоз, блювання, серцево-судинний
колапс, порушення свідомості аж до коми, судоми і пригнічення дихання, яке =
може
спричинити зупинку дихання. Повідомлялося також про виникнення серотоніново=
го
синдрому.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK;mso-bidi-font-weight:bold'>Лікування<o:p></o:p></sp=
an></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.=
0pt;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK;mso-bidi-=
font-weight:
bold'>Слід проводити загальні заходи з невідкладної допомоги. Залежно від
симптомів необхідно забезпечити прохідність дихальних шляхів (можлива аспір=
ація),
дихання і кровообіг. У разі пригнічення дихання вводити антидот налоксон. <=
/span><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-language:UK;mso-bi=
di-font-weight:
bold'>У дослідженнях на тваринах виявилося, що налоксон не впливає на судом=
и,
тому вводити внутрішньовенно діазепам.</span><span lang=3DUK style=3D'mso-b=
idi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK;
mso-bidi-font-weight:bold'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.=
0pt;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK;mso-bidi-=
font-weight:
bold'>У результаті гемодіалізу або гемофільтрації трамадол виводиться з пла=
зми крові
тільки в невеликій кількості. У зв'язку з цим у разі гострого отруєння
препаратом Трамадол Калцекс використання тільки гемодіалізу або гемофільтра=
ції
для детоксикації неприйнятно.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:9.0pt;mso-bidi-font-size:12.0pt;mso-fareast-fo=
nt-family:
"Times New Roman";mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>П=
обічні
реакції.<o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:RU'>Найчастіше повідомлялося про такі
побічні дії: нудота і запаморочення. Вони з'являються більше ніж у 10 % пац=
ієнтів.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:RU'>Далі згадані побічні дії наводят=
ься
відповідно до класифікації систем органів, а також за частотою виникнення
(MedDRA): дуже часто (&#8805;1/10), часто (&#8805;1/100 до &lt;1/10), нечас=
то
(&#8805;1/1000 до &lt;1/100), рідко (&#8805;1/10000 до &lt;1/1000), дуже рі=
дко
(&lt;1/10000), частота невідома (не можна визначити за наявними даними).<o:=
p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>З боку психіки:</span></i><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'> рідко &#8210; галюцинації, сплутаність свідомості,
порушення сну, марення, занепокоєння і нічні жахи.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:RU'>Після застосування трамадолу мож=
уть
з'явитися психічні побічні дії, ступінь тяжкості та вид яких відрізняється
індивідуально (залежно від особистісних особливостей пацієнта і тривалості
лікування). Вони включають зміни настрою (в основному ейфоричний настрій, і=
ноді
дисфорія), зміни активності (зазвичай зменшення активності, іноді збільшенн=
я) і
зміни когнітивних і сенсорних здібностей (наприклад, розлади процесу прийня=
ття
рішення, сприйняття).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:RU'>Може виникнути залежність. Також=
 може
виникнути синдром відміни препарату, подібний до того, як при припиненні
застосування опіатів. Його симптомами є порушення, тривожність, нервозність,
безсоння, гіперкінезія, тремор і симптоми з боку шлунково-кишкового тракту.
Інші симптоми, які дуже рідко спостерігаються при припиненні застосування
трамадолу: напади паніки, сильно виражена тривожність, галюцинації, шум у в=
ухах
і незвичні симптоми з боку ЦНС (наприклад, сплутаність свідомості, жахи,
деперсоналізація, дереалізація, параноя).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>З боку нервової системи:</span></i><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'> дуже часто &#8210; запаморочення; часто &#8210;
головний біль, сонливість; рідко &#8210; парестезія, тремтіння, епілептичні
судоми, мимовільні скорочення м'язів, порушення координації, непритомність,
порушення мовлення. Судомні напади зазвичай спостерігаються після застосува=
ння
великих доз трамадолу або після одночасного застосування препаратів, що
знижують судомний поріг; частота невідома &#8210; порушення мовлення,
серотоніновий синдром.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>З боку органів зору:</span></i><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'> рідко &#8210; міоз, мідріаз, нечіткість зору.<o:p=
></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>З боку серця:</span></i><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'> нечасто &#8210; брадикардія, тахікардія, тріпотін=
ня
серця.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>З боку серцево-судинної системи:</span></i><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:RU'> нечасто &#8210; вплив на серцево-судинну регуляці=
ю (відчуття
серцебиття, тахікардія, постулярная гіпотензія або серцево-судинний колапс).
Такі побічні дії в основному можна спостерігати при внутрішньовенному введе=
нні
або у пацієнтів, які піддаються фізичному стресу. Рідко &#8210; брадикардія,
підвищення артеріального тиску.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>З боку дихальної системи, захворювання грудної клі=
тки
і середостіння:</span></i><span lang=3DUK style=3D'mso-bidi-font-size:12.0p=
t;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'> рідко &=
#8210;
пригнічення дихання, задишка; частота невідома – гикавка. При значному
перевищенні рекомендованих доз і одночасному застосуванні речовини, яка
пригнічувала ЦНС, може виникнути пригнічення дихання.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:RU'>Повідомлялося про загострення ас=
тми,
проте причинно-наслідковий зв'язок не встановлений.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>З боку шлунково-кишкового тракт</span></i><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:RU'>у<i style=3D'mso-bidi-font-style:normal'>:</i> дуже
часто &#8210; нудота; часто &#8210; запор, сухість у роті, блювання; нечаст=
о &#8210;
блювотні позиви, почуття дискомфорту у шлунково-кишковому тракті (відчуття
тяжкості у шлунку, здуття), діарея.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>З боку гепатобіліарної системи:</span></i><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:RU'> дуже рідко &#8210; в деяких окремих випадках
підвищувався рівень ферментів печінки, що збігалося у часі з терапевтичним
застосуванням трамадолу.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>З боку шкіри та підшкірної тканини:</span></i><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:RU'> часто &#8210; гіпергідроз; нечасто &#8210; шкірні
реакції (наприклад, свербіж, висипання, кропив'янка).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>З боку скелетно-м'язової та сполучної тканини:</sp=
an></i><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:RU'> рідко &#8210; м'язова слабкість.<o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>З боку нирок і сечовивідної системи:</span></i><sp=
an
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:RU'> рідко &#8210; порушення сечовипускання (дизурія і
затримка сечі).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>Загальні порушення і реакції у місці введення:</sp=
an></i><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:RU'> часто &#8210; втома; рідко &#8210; алергічні реак=
ції
(наприклад, задишка, бронхоспазм, свистяче дихання, ангіоневротичний набряк=
) і
анафілаксія, зміни апетиту; частота невідома &#8210; гіпоглікемія.<o:p></o:=
p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:-7.1pt;margin-bot=
tom:
0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:normal'><u><span lang=
=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>Повідомлення про підозрювані побічні реакції.<o:p>=
</o:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:RU'>Повідомлення про побічні реакції
після реєстрації лікарського засобу має важливе значення. Це дає змогу
проводити моніторинг співвідношення користь/ризик при застосуванні цього
лікарського засобу. Медичним та фармацевтичним працівникам, а також пацієнт=
ам
або їх законним представникам слід повідомляти про усі випадки підозрюваних
побічних реакцій та відсутності ефективності лікарського засобу через
Автоматизовану інформаційну систему з фармаконагляду за посиланням: <a
href=3D"https://aisf.dec.gov.ua"><span style=3D'color:windowtext'>https://a=
isf.dec.gov.ua</span></a>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'><=
o:p>&nbsp;</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>Т=
ермін
придатності.</span></i></b><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:RU'><o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:RU'>4<span style=3D'mso-no-proof:yes=
'>
роки.<o:p></o:p></span></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<span
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:RU;mso-fareast-language:RU'>Не застосовувати після закінч=
ення
терміну придатності, зазначеного на упаковці.<b style=3D'mso-bidi-font-weig=
ht:
normal'><i style=3D'mso-bidi-font-style:normal'><o:p></o:p></i></b></span><=
/p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
UK
style=3D'font-size:9.0pt;mso-bidi-font-size:12.0pt;mso-fareast-font-family:=
"Times New Roman";
mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
UK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>Умови зберігання.<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:RU'>Не потребує спеціальних умов
зберігання. Не охолоджувати та не заморожувати. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:RU'>Зберігати в недоступному для діт=
ей
місці.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span style=3D'font-size:9.0pt;mso-bid=
i-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:RU;
mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>Н=
есумісність.<o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:RU'>Розчин для ін'єкцій Трамадол Кал=
цекс
не можна змішувати (застосовувати в суміші) з розчином для ін'єкцій або
інфузій, що містить диклофенак, індометацин, фенілбутазон, діазепам, мідазо=
лам,
флунитразепам і гліцерилнітрат.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
UK
style=3D'font-size:9.0pt;mso-bidi-font-size:12.0pt;mso-fareast-font-family:=
"Times New Roman";
mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormalCxSpMiddle style=3D'text-align:justify;line-height:norm=
al;
mso-layout-grid-align:none;text-autospace:none'><b><span style=3D'mso-ansi-=
language:
RU;mso-fareast-language:RU'>Упаковка.<o:p></o:p></span></b></p>

<p class=3DMsoNormalCxSpMiddle style=3D'text-align:justify;line-height:norm=
al;
mso-layout-grid-align:none;text-autospace:none'><span style=3D'mso-ansi-lan=
guage:
RU;mso-fareast-language:RU'>По 2 мл в ампулі з безбарвного скла I
гідролітичного класу з маркувальними кільцями та з лінією або точкою розлом=
у.<o:p></o:p></span></p>

<p class=3DMsoNormalCxSpMiddle style=3D'text-align:justify;line-height:norm=
al;
mso-layout-grid-align:none;text-autospace:none'><span style=3D'mso-ansi-lan=
guage:
RU;mso-fareast-language:RU'>По 5 ампул у чарунковій упаковці (піддоні) з
полівінілхлоридної плівки.<o:p></o:p></span></p>

<p class=3DMsoNormalCxSpMiddle style=3D'text-align:justify;line-height:norm=
al;
mso-layout-grid-align:none;text-autospace:none'><span style=3D'mso-ansi-lan=
guage:
RU;mso-fareast-language:RU'>По 2 або 20 чарункових упаковок (піддонів) разо=
м з
інструкцією для медичного застосування у пачці з картону з контролем першого
розкриття у вигляді самоклеючого стикера на кожній частині пачки, що
відкривається.<o:p></o:p></span></p>

<p class=3DMsoNormalCxSpMiddle style=3D'text-align:justify;line-height:norm=
al;
mso-layout-grid-align:none;text-autospace:none'><span style=3D'mso-ansi-lan=
guage:
RU;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
UK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU;mso-no-proof:yes'>Категорія відпуску.<o:p></o:p></s=
pan></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:UK;mso-bidi-font-weight:bold'>За
рецептом.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'font-size:8.0pt;mso-bidi-font-size:12.0pt;mso-fareast-font-family:=
"Times New Roman";
mso-ansi-language:RU;mso-fareast-language:RU;mso-no-proof:yes'><o:p>&nbsp;<=
/o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
UK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU;mso-no-proof:yes'>Виробник.</span></b><span lang=3D=
UK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>Виробник, який відповідає за випуск серії:<o:p></o=
:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:RU'>АТ «Калцекс».<o:p></o:p></span><=
/p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:404.25pt;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
UK
style=3D'font-size:9.0pt;mso-bidi-font-size:12.0pt;mso-fareast-font-family:=
"Times New Roman";
mso-fareast-language:RU;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:404.25pt;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
UK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU;mso-no-proof:yes'>Місцезнаходження виробника та адр=
еса
місця провадження його діяльності. <o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:404.25pt;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:RU'>Вул. Крустпілс, </span><span
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:RU;mso-fareast-language:RU'>71Е</span><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>, Рига, </span><span lang=3DEN-US style=3D'mso-bid=
i-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-US;
mso-fareast-language:RU'>LV</span><span lang=3DUK style=3D'mso-bidi-font-si=
ze:12.0pt;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>-1057,
Латвія.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:404.25pt;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:9.0pt;mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'><=
o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:404.25pt;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
UK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>Заявник.<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:RU'>АТ «Калцекс».<o:p></o:p></span><=
/p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:404.25pt;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DUK>Місцезнахо=
дження
заявника та/або представника заявника.<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:404.25pt;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-fareast-language:RU'>Вул. Крустпілс, </span><span
lang=3DLV style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:LV;mso-fareast-language:RU'>71E</span><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-fareast-language:RU'>, Рига, </span><span lang=3DEN-US style=3D'mso-bid=
i-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-US;
mso-fareast-language:RU'>LV</span><span lang=3DUK style=3D'mso-bidi-font-si=
ze:12.0pt;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>-1057,
Латвія.<o:p></o:p></span></p>

</div>

</body>

</html>

------=_NextPart_01D92EA1.A6713670
Content-Location: file:///C:/680A9711/UA164680101_3D71.files/preview.wmf
Content-Transfer-Encoding: base64
Content-Type: image/x-wmf
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------=_NextPart_01D92EA1.A6713670
Content-Location: file:///C:/680A9711/UA164680101_3D71.files/item0001.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?>
<b:Sources SelectedStyle=3D"\APA.XSL" StyleName=3D"APA" xmlns:b=3D"http://s=
chemas.openxmlformats.org/officeDocument/2006/bibliography" xmlns=3D"http:/=
/schemas.openxmlformats.org/officeDocument/2006/bibliography"></b:Sources>

------=_NextPart_01D92EA1.A6713670
Content-Location: file:///C:/680A9711/UA164680101_3D71.files/props002.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?>
<ds:datastoreItem ds:itemID=3D"{D60E1A2B-2C1D-43DB-A35B-EA96DED2F533}" xmln=
s:ds=3D"http://schemas.openxmlformats.org/officeDocument/2006/customXml"><d=
s:schemaRefs><ds:schemaRef ds:uri=3D"http://schemas.openxmlformats.org/offi=
ceDocument/2006/bibliography"/></ds:schemaRefs></ds:datastoreItem>
------=_NextPart_01D92EA1.A6713670
Content-Location: file:///C:/680A9711/UA164680101_3D71.files/themedata.thmx
Content-Transfer-Encoding: base64
Content-Type: application/vnd.ms-officetheme
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------=_NextPart_01D92EA1.A6713670
Content-Location: file:///C:/680A9711/UA164680101_3D71.files/colorschememapping.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"yes"?>
<a:clrMap xmlns:a=3D"http://schemas.openxmlformats.org/drawingml/2006/main"=
 bg1=3D"lt1" tx1=3D"dk1" bg2=3D"lt2" tx2=3D"dk2" accent1=3D"accent1" accent=
2=3D"accent2" accent3=3D"accent3" accent4=3D"accent4" accent5=3D"accent5" a=
ccent6=3D"accent6" hlink=3D"hlink" folHlink=3D"folHlink"/>
------=_NextPart_01D92EA1.A6713670
Content-Location: file:///C:/680A9711/UA164680101_3D71.files/image001.png
Content-Transfer-Encoding: base64
Content-Type: image/png

iVBORw0KGgoAAAANSUhEUgAAAUgAAADrCAIAAACEiZiQAAAAAXNSR0IArs4c6QAAAAlwSFlzAAAO
xAAADsMB2mqY3AAAXRpJREFUeF7tXQVcFOsWd6137e7uABQLQRAQRREkLExUULFbCRss7BbsRgRU
WjBASsUWu7u7C933353dZbZna3aAmXff/XHhy3O+88WJ/+Fwuf/ysR9LAZYCuYsC+XPXdNjZsBRg
KcCjACvY7DpgKZALKcAKdi5kKjulXEgBLlelSeXPp2IFlVpnCzOIAiyjGcQM1YfC4ahUh8Mqz1Si
V84rTMizissi502THbE4BUhXcXZHz5WLAyLNSnWu5KzCSZEEm2U/o9gvc59VY/NVowqj6MAORi0K
cLj//pJ39I/v32ecPadWU2wl3VKgYsUKLVq0UK+PP79/JSYlq1eXrcU4CuAM5nINmzatVqO6vLFJ
vrHPn7/g2K1bhYoVGTeZPDwg6EG+fv3ap2+/RQsXqEeGd2/eGjVrVrZs2QIFC6rXAluLORTAenj/
7n3gxo2O3RzkC7b4iU0I9tOnT/IXKMCcmeTdkeAizX8iLVu+4t27d2oL9vu3bw2NmqWlpdatVy/v
EjMXzdzc3NzHd7oCwc7PalYYzW4tKT6Ihzb73GY0r7U6ONZBRavkZBtjKcAMCrCCzQw+sKNgKaBV
CrCCrVVyso2xFGAGBVjBZgYf2FGwFNAqBVjB1io52cZYCjCDAqxgM4MP7ChYCmiVAqxga5WcbGMs
BZhBAVawmcEHdhQ5kQIMdgxgBTsnLih2zMyggJbch3QxGVawdUFVtk2WAnqmACvYemYA2z1zKaD0
po0CSsvoaXqsYOuJ8Gy3zKeA0pu2CMSCeeLNCjbz1xc7QsZTQOkWQPsMWMGmneRshzmHAj9//Lh8
OTM9Pf3cufOfP37MOQNnccVzEK/YodJIgWtXr/lOn9GkadOBAwesWr3a29urcZOm7h5D4+IO//v7
l8aBqNkVe2KrSTi2Wm6lAGCklq9Y2blz5x8/foSHH7iSmRkWGnr8+PGrVzI7WFvPnj3LyrrDoYiI
v1lZKlOAxqc4K9gqc4etkLMpoBAl8sO7dyNGjQncsH7T5s2rVq5o1aqlCImkbPnygwa5paWmDh02
bLrv9E62nY8cPaqaVpzGpzgr2Dl7lbKjV5kCJOl6/vTZ9h07J0+e4ujk3NvVFT+0t7R6/vxZXFyc
g4O9zJb/K1JkyOBBGadOdu/RY+SIEQMGup09eza7JI1nsuKJs4Kt8sJgK+R4CnC59+7emzlrdjsL
8xs3bli0bz9lypRevXrXb9BgydKlMVFRDRs2FMxRjqCWLF16/LixJ9PTDQwNe3TvMc3L++6du7wq
is9kUWu6l39WsHP8KmUnQJUCfHF6+/rNgkUBtp1tS5UqlZ6atmRxQI/uLtbWVn1ce48eNdLevmvB
QoWyG5QQVHGBrFylynRfn9TU1P/++8/GxmbhooCXL14oGoyoNd3fyVnBproq2HI5nQJZWVm7du1u
Z2EBLOcTSUnTpk5RgMste7KyBLJ2ndrz/P3iE+LfvnljbmGxfkPgl0+f5NJK92c10TUr2Dl9ubLj
l0UBKWdP4Go7Obvs4n07geJcs1YtJYSTlkCFF+mmTZuuWLE8NDTs4sULJqZmmzZv+fr5s4wudH9W
s4LNikTupQBJfn79/Lly1eoe3bs7dOsWFxtjampKadrSEkjhIg0t+pbNvO9IQoKpWbut27Z/+/KF
UnfaLsSe2NqmKNseQyjAl0P4mTg6OcUfPhx3OG7M6FGF//c/GkZnYWEeHha6bPny4L172lm0x/0f
Hmw09EvughVsmgnOdqcbCsh6u+4N3mdvb9+pk21kxCEDAwPddCynVQ7Hzq5LQnz8rNmz161bB8V7
aFh41u/fvNISQ9XNq5sVbFrZzXamTQqQRUL85owTctbsOTOm+64PDPSaNhXGZ0G/upEiyUkJe4GC
vVfPHinJJ8aOG+83Z461jU1sbBxXYgy6eXWzgq3Nlca2RSsF5IgElNKjx46LjY6OOBTRTcLPhJ+n
ktZB5stH+LScPnWyb79+48aNdXbpnpycousxsIKtawqz7dNKge9fv3qOGn3/3t3oqCjjFsa8viXk
XzcnpNgkZXVRolSpsWPGwKfFrJ3ZwAEDPEeMRNyYjJu5lqjFCraWCMk2o18K8M/h379+TZ427dPH
j6H796tso6Zl/PBp8fXxSUpKKlG8eFc7O7wXnj59qoueWcHWBVXZNmmnAIeDcKvpM2c9e/psz66d
FStVon0ElDvkcus3qL98+bKDEYdu3uQ5tK5Zu06RTwvlhskFWcFWi2xsJeZRIGDJ0vPnzm3fuhVh
WPoZHcXXu/CibmpiEhoSsnbd+pB9weZ8tbk6oaBypsoKtn7WANurdikAW3FkRMSeXbvKV6yg3ZZV
aE3V1zuHw8mfH8nrkxITJ0ycNGP69O49ep4+fVqFHuUXZQVbK2RkG9ETBfiH5PHjiQsXLty1cyel
dzXFc5XGCf3vv/+Gerinpaa0at0asWJe3j6IJ9Wwf1awNSQgW12vFOBwrl+/PmbMmK1btzRu0pjS
UPRh8aIysEqVK8+ZPetwfPzzZ8/aW1nCHRVYLlQqyizDCrbapGMr6oMC4uft+7dvhw0b5j9vnrm5
uT5Go/0+mzdvtmf3rtVr1m5Yt65zl66pqWky+qBw6WAFW/u8YVvUIQVI71h4aHr5+vbo2cu1dy/V
eqT4GKYgP6r1S7E0hwO/muSkJHi59+vbFyYxxJCLVSXGr3B4rGBTJDZbTN8UkFrHS1esKFq02KQJ
4wUjoyCHXz99lhQSBdOiKP/aJYxwFsVLlZw8aeKRo0cePnxoZW198FCEZD8Kh8cKtnbZwramMwqI
r+M9e/dCmbzQ379AwYKCLinI4drADbfv8jGMKHyAT0IUN4WCWi0iPguEee/asX3BwoV+c+eOHDXq
0cNHos6gU1fQMSvYWuUK2xgtFDh2PDFg4aKNQUE41qh3+PP7933BwS0JP1MK36HIyJu3blEoqNsi
MIm5uDgnJyVWrFjJpqMNQtaIS7hkMIn4KFjB1i1X2Na1TgG4WI8ZPRrwwHXq1lWp8fMXL9p07JQd
6aWs8u3bt6tWqZJdisJVX1mT6v+9dNmy/n5zt23bvmb1avehw34TEaDyP1awxWmjV+apz/Y8U/PZ
k6eDBw+ev2BBu3ZmkpNWxrsHDx82aNCAOqkyL19uUL8e9fI0lLSyskw8drRx48Zv375lBVsVglN4
p6nSHFtWmxRA5NbI0aOHuLv37tVTRrvKePfp0+dy5cpRH9CnT5+qVauWXV5Z+9Rb1qRksRIlvL2m
VahQkRVsTcjI1mUKBbL+/Jkxe05zY+MJ48bKtvQoO7H//PmTXyScygpj2iiM9y1T5i8+jkKFhCpD
OeNj6LhpoybsH3Bdkg0oSdsg2I6UUoDLnb9w0c+fP+fMmsETNr58gmvgnSAuCoKq7EQtUqTIL2VP
U/JAgBauie+X0jnptECeFux16zcYGBl16tjJsFmzwKCNOiU027gmFFi5es3VK1eWLQ4oVKgwrx0u
d/OWrUbNm3e06djUwBB+WopVxETXFStWeCEC9Fe2C6B81WrV3rxW8pTVZFI6rZt3BTskZP/aNWu2
bd9+6+aNLVu2rlyxAnFzOqU127h6FNi5a3dMdNSmoEA8L4ljOSIyKmDRwg2BgTdvXN+1e3dQYODu
PXuVNl67Vq3r164pLSYqgBy6z148p16eUSXzrmDv37/fy9u7Y0cbYNZ06tRx6rRpYWGhAt5QeIAx
iou5eDDIR71u7ZpdO3aSo6wPHTo0ecpUIJCUKlOmQwdrX1/fPXt2KyWCkYFBRkbGx/fvBU90ZVyu
UaPG48dPiAuC0sZpLqD0hpJ3BfvRw4fVqlYV8aN6tWrZbj0U7mk0MzJvdgfHL2Sc30mOx+TL2P37
98n6avz85IlygKGChQsjRWZkTKzgNa6MyxBsWMh4lFdWUi53FCYP0YSnit3O0HLeFeysv1n5C2RP
P3/+/FrEr9CEZ3m3rlTklufw4UuXLoNbZTZN+DLG5f4jr2zw7t+/f1To5uTYbdnSJUiCraQwfyRN
Gze6psrVXUaboh1B7a2Byqxklcm7gv3nT1aB/AVENClYsODvP0q8edQlMluPGgXEV/+iJUudXFwA
uy9dOSvrb7bhCqdT/vxZWX/S09PxGkfKS/hU23Xt2ratqbFxC1NTMxeX7sAnWblqFTC9a1SrDuez
2X5+StTd/JHUr1//8sWLMLNRG72MUj++fYPDudrVNamYdwUbuRcLFMgWbPz8+7f6LNSEB2xdaQoc
OXo0KfH4lIkTZBLn718B7x7cf7Bl67YlS5f8+P5jyBB3hIVAJFu3bj1k8BAfX585c+eMGz/etnNn
QIImHk9EnvrWbdoknzgRHho23HPkg/v3FVM+f4EC5u0tbty8SeV4lyiD29+BAwfNzC1mzp4t+BP5
PkLDox23GvI/586dq1K58t+sPxK/z33/Wbt2rZSUFN68/v3Fv5OTk+vWrcPYaS5dtszH11ft4b19
/RpsvXvnjtot0Fnx+9cvbdq0QbYtgjXS/xgaGiBD/UA3N0zK1dU1aONGqEKVLtof376eOn0qMCio
V+9eqFizRg0c4+/evFYwta3btu3ctUuluf/6+SP8wAFb20448NetX4+5qFSdYmF41EZFRysonHdP
7N+/fhcqzE9xzsfKKVy40M8fP2Vsrux5SjsFgjZvMWlrAqW3tNYKV2iEN33+9Hnb1q0Q/rS01P37
Q8xM204YPx6OZXJHyj8h/yta1LRt25EjPMNCQ0+fPjV77lzgH7Y1a7di5Sp5F+aWLVpcuCAVuSnn
vMWDHE0Bt2zF8mUDB7pdPHcOaQCLFCtGO/14HeZJweZy8fiBwaAokdKJ77RUtGhR/AaRfQJR1ws3
2E7z5YNtAvatyRMnShPj6NFjHWw6rlq5AveXixfOjx83tm49XpAGbtpQkfz7+1cu/aR0V8iPDfxA
3PaDg/d++PChY6eOboMG7wsJefwoO+AZrTUzMkTuDslcmaTWYDxDDOmy5SvatWtn18UODjDr129I
TUkZNMhNpZBSrXM+Two2h/PtG0+AixXl76Z8PhXn76xfv37TOonZBlWiwLYdO5D+hpBY0Qe/Ud/p
Mzw9hw9x9wBm0JmzZ7+ROIX4zatXMtU5GzkcHPvz/P2uXbni2rv3pYuXbDp2tLa2nuvnD4+XpBMn
rl2/bmFhcTwxifsPT7Z/cEBGLOeJE8nbt++YM9fP3t4Bfm/Dhno8evRw4qTJly5eXLpksaVlezzO
VZqyLgrnScGGAH/jCXCxYkVFNIUjMU+w+b9nP31RAIaoHdu2ufXvTx7A0ydPXHr0gK4LCjBIEXi0
d/fuj58+ZZfhckPCwjVx+IdPm6Njt8WLA25ev75s2fK6dercuXNn7dp1rq59gM0wbOjQqlXh9FCt
QaNGVpZWw4cPP3jwIG7+vXv3RjaPWzdvwoURuGvlKugpUYEsbnHw/ib/Hi4Bjt26PX36hAm7ju6W
F/ZmZE5+8OA+IJ2JXpD2qXbtOrFxsS1atNBdv2q3jMveu3fvFi1coF4L7968NWrWLDU1tR7DAowl
pgNQzvnz5yckxPN+z38iQdSdXLpbWlmN9Bx+49YtuIIhFDkuNhZHayE4jhcuXKpUKcgcZC8qOgrH
r3r0Ie8Rgoe9MKoECwNP+h8/f+ClhrCQkiVLUodq0HQw8usDldXHdzqSDcgrkkdP7A+fPhYvUUIk
1aBO4f/9r0TJkh8+fNQdM9iWlVIALkN/xZ/K8xYsvH/vHk5FLx/f9PST+GvNmjWnTJ3apnXrpk2b
VKhQ4eOHDwcOHoQpG2E8KKm0CyUFyC4lfCUZFgayi9RAr7VqISUYE6SayhzzqGB//PixcuXKEgSq
WrXqh48fGegYTIWRuaNMcwPDO7dvC/JgcDh4zeImPNXLa9uWzfv27vGbO2eE5/AqVSrDM9zBwb67
iwvyTnt5Tdu2dcud27esrKycXVxwF9OUFCKlN+3uYpqOnFQ/jwr227fv6kuh5OA3PMSZnMxOLa4M
vTQFTbJr374xhw8T22vwvn2Q6kkTJ5QsXVrEl0ePHhcsyLdTkr5de4PLli07f8HC0WNGaxpETXEB
0OBkogEP8qhgv379Gi7+EnSrXr06fq8BMdmqWqBAj+7d169bBwsTXtcxUVFuA8QUaRB4Swvz8ePG
SfQEO9OlS5ecHbvhPXw64yzvrxQFj2Ix6ZlRlH8tkESdJvKeYPMZ+fLli4oVeahRZ86cdfcYSqQ4
xG94gfhqc1od+rN1JClgZmbaslWr4P2hT58/xyGcnema4AuCPzgc42ZGYNOFCxfhRpqSkopfd7Sx
gTMJ/go72XMCTYGi4FEsRh5mTlgheU+w+Yy8kplZmZ8bPS09/Uh8fFr6SfwMN8PMy5eoLghWJHVG
gQnjxi0OCCjyXxHoop88fizoRyiBw4YPTzh6DGw6eepUQnx8ckoyCli2tzA3M+Vv2S8JlwTtfDJl
WHovYJ6o5z3B5jP86dOn5fnp0T0GD4LD8NAhg/EzICyfPdM0fal21lPebsW4hXH/AQO279wJi87o
MWMlojUQel2JvykPGtB/1Zo1I4YPx+mdfuqUpbX161evYPQ2btZMa/SjeJ5TLKa1YSlvKO8JNjZX
LrdGjZrP+ag3wGF3de1dho9Kiytc9eqSD2/lJGRL6IAC40aPioqMQJwGEtN17mK3ZMnShw8eEv0c
P3bUtK0JfoBGrU/vXrwnFYfz/t17WJijYmJ69+mjPEs28w5YrZMw7wk2NlcOx6V7d2DuSFDz2LFj
QNjQOonZBtWgAICQEL81YcIERwf7Y0eP/v7zB+7ccDUNCz/w7v2HbIQzPjfRvrVl+7Hjxi9ZvGTU
iBHKu2PeAat8zCqWyHuCzSeQVfv2SceP8+CviI/LhTfy4dhYy/btVSQgW1zbFBAep4jugp8cHFRq
1a41c8b0i+fPd+hgHRMd7WBv7+3lBVftmNg46M+uXLkSHRPrOWr07FmzVq1a1bhJY0XqT4mzOvce
3XlUsBHQC1+lm7dvC1Ylh4OfoW5t3sxQ2+uUbU9FCpCO07CQkOvXriLoCrKKizeSRe/cuePSpYvg
3dcvX44fPz5y5MgunbvgmZ2emoq8P61a8t2BFRzIEn/KvUd3nhRsLrdgoULwJ/385cv6DYGLAgIA
MP7ly9eChQoWKvw/FZchW1yHFChavPiaNWvmzpl7/cYNUTcVkHWyUiXEYBkaGuLpNM3bC3l/gIeD
cGio3ICINHPmrP2hYXdu38nLlss8Kdj58p08eerH9+8LFyxAKG/ZsuW+f/vm7++X9SeLMIpmf7n3
qqZDcVSvaTmkbtasmZ+//7hx4759+UI0fOnS5VevXi1durRQwYIwdAPQ6uyZM4jHtjA3xxkeFxOD
QEvEZvUf0L9Vq9a4sUdERL54ToIHzxs8zYuCfe/e/XFjx06cPPnEiRO169SuVbOmmZkZfob34vjx
4xFwm70yc+9VTT3p02Et+aTu28e1nbmF/4KF6B1ACLh+jxk3LiUlmeCdebt2cCOfMWvWxAkTcGgj
dtKuS2e8yc+ePbtr1y74/wO9GBLeuXNnwJskJ6dgQ9fhLJjTdF7DPAOSVqNGjaZ5ecGjWGLuAM2a
OWsWMq0eioigCD1FW7E8hXkmTdUf37+5uLjMnjPHoGnTiZMm/f6FIEpxLLR/f/3n+derV3d/aKh0
dTAUma4nTZpkbt6uVq2agDHdsXPn1atX/v3NUp+DcvDYNGqQcptKMc94EM25E8xQFo3giwLT6LZt
2+Ry9N/fPXv2AOcQD2/1OSQLf0/D1vK4YIN6ixcvhmsgdl4FoIWANIRsQ/6l+QvjGaK1P7x7+/DB
AxQDeilWgpGR4azZs4EKqBjSkCrvKIsl1QblL6Q8LNhSRElLT6tRvfrZs2eUkvXihQt16tROTExU
WpK2AnlcsME7pGrBpRqiiFxrCsiOcxiyjRxAEmVwyAOcdPLkyaLfv3j+rGfPntjE27dvj8b79OkD
AFOg9Gb9+a2IrTRKr4JhKBXsAnPnziG/CxAFgQhYzJ+xmYHVfsUcOhSB/ImD3dyugvlXruK5dfTo
UcBZAcI6LS394sWL9+7dQzjn36y/9evXe/32HWK28X5TuzvtVoRf9I8fPzp17Khes3hYBgYGenh4
QNukXgv6rRUVFV2mbFlfb6/8BQtNnTr1HzffieTkxKTEo0eOws//wsWLmZlXvnz+AiVovbp1vn7/
ASfCDlZWZLtXgQIF27YxwflcvkJ5I0OeURNIG8A5gw/ikSNHypYrZ92hw48f3zdsWA8vtydPn336
9LlkieIlS5USTFwIqKLIliYqo3ti4dZp0b59o4YN5XWVh5Rnnz9/BudatGx5PDERcdd4S3fr5tCv
Tx/PYcMQG4jwIKSAevHyZXBISAcbGx4gzufPumcQ2wMlCiAz9p8/v1u0bIXdbfLkKcbNmwMVqH/f
fsBdGNi/X6eOCO0yBu8OJyS49OyZlpqCYgSqNLl1OLrgLTbd1/eGyHjG4fTs2SPj1MlRo0fjPDt+
7PicOXOPHT1i0qbN+fPnu3Sxg1Ft8ZKl2PqB06J8oIwKDsm1b2ypq/jQYUMR0fX82VOl9+cvHz86
OzvjbiYPsF5pC1ovkMev4hMmTsQD++njx0oJ++3LZ2jX7B3s5ZWcN39+F7su0MZJFACy/9p16/Dw
hpAjufLly5dwJ8ejbPOWLVg5+D20dytWrsTx/urlC6XDkFtAeJPXSG/H/af0Kp6HwAy9fXwBRgeP
JTg2wFJSpVLlMmVKFytSlMDZgjkUuEi4wr189Sox8ThuYsjkAGBa5fs0LSXyCJihPFr6+c/7/v07
0mhJ8w7p+H79+i3iXVJS0udPn/DmAhKwzNYA4eDQrVsn286+Pt7SBeCgCpv5kydPevV2xYvNw2No
DxdnPEsBPOzarx8nPweWs8Nxsf/73/+sO9hghdSrWxf/r1KlCpVoX1wDb9++c/3mTVwHIg4dwk0B
MUjqLR+lYIZ5RbBh/5zrPw+IdLh433/w4OGjh4j+g0Lh+bNnCPotgfdWyZLAVKlVqxaw0Fq3aLF5
27Zv376xgq3estNurWdPni4ICAAa6bgxYyR4B2kHuiDibcm82x0cjLBcZNWUNwzoU5wcnXbv2WNt
bSVdBhEEY8dPaNCwoeewoesDg4DBFrBoUZ26dW7euNnNsVtoaFjLli2Q1SDz6tVbt25BRE+f4gXz
N2nSFNBaGGSxYsUAZV24EA+86U9WFvYRODi+ffvm2tVriD9FAdsuXZo3a2bToQOeBmoTihXsfKcz
MkJC9kdGHAK6sBWw4OcIk6QpJGrA4iVfv36dP89frBSN2hGJ0eWqE5syGaGjDg0LDwvdjw3X1Kxd
wCKej4rSb9XqNYoFGy2AngcPhCOJHxmpVtQyIMqHDvfs3KULsoUgRyfCS7Zs3QJc6sioaOz1hw4e
BGipSKkGb1ac8M+ev3j/4T1QbqHA+/7jB+6AuEog02ORIsgsVAw6y0oVK8KhhgehqQ2vJ6WCnXvt
2Nx/J0+eHDx4MKyXMJN8+vAej6s5c+dSfB3Bjj1j5kyKhWkoltfe2GfOZAz39ATa0ZatW9+/fbNs
+XJvHx+KdIaGDPjE2YVlGai+fPqIQKDde3bLa/Pli+dYOUjihwIwkeJnnLf4ef2GDdCovX71kuJg
dFRM6Rs7d2rF4U48avQYRPN2tbdPT+MlUiLsFsB8l7ffI+8pcrgoPQ3YAlqmgBRH4BaKdDkjR4yE
/Jw8mY4zEzAYChiH8SBrlwTvrl+79kaESynrhCxesiS060GBgfICRSpVrrxkyZIpkyfjLo28vAsW
LJg8dSoe+aNHjbR3cHAbPPjt6zdUSaEP7/ScI9jUqJOZmTnNy9vNbaCpqWlqSjIQNgQBW7K4i7gC
PJmwjFq2aAl7JnDwZsyc9Ylv2EAIJ1W2seU0oQCJzrBCTZ8x07W3q5GRUXpaav9+fWXek4nekFYR
CagnTZ7SqmUr8A7pu7y9fUTChlQ20HIhBdftW7fkjc7RwQFP5UuXM+UVwAscPup7gvehANLi4tDe
sWs3fp42dYqNTcderr0Bw5RdV7Q+pReqPtZSzhFsZdTBWxp+gv379W/cuPFpXMIHufGWhZxa2OOR
jdWkrSnSr965c3vxkiW4+8XGxiJlzIhRo7N+/wbDYDvNy3F/mkirCnX5YgC8BJyf3bv3wFs649Qp
nNJ4mMojPg5nRGW2NTMbO2YMTuYFCxeeOnUy/nB86TJl3IcO/fXzJzZl285djh0/hicu3smI4nxw
/4H0kJDfo62paeaVK5J/IknmUHd35OWCNhtlgNa0ZfPmVy9fYmBe06Y6dHOEofvqlauC6orXpwKx
V4FYKhTNOYItf1IpqamAoR3hOaJFi5YQaSwL5FiTLi46hJHICtK7YtmysePGWVi2RzQ/9uPqNWo0
bdp0zuxZuPUdTjiC6gBUeSyCyFSBpGxRFShw+swZhGS4DRzYsFGjM6dPweEkO/usuKgQt3Hcp8ZP
nIh4W4ActjExCQ/db2fXBcl3AJwC81WlypUio2OIkg0bNpw1c8apkyf/99//bDraID+mIM8uSW7r
1a9///59yVOX1C+ahc4s6QQPCBW39zFjx/IObX4Bp27dSpUu1bNXrwT+asn+pBxjeH8StansfFKB
dgqL5mDBxs6dlHSiX/8BXtO8sDHDKujhPkRpUmJcn7r37AmVxpGEhPMXznt7eSOan0wixO6npqXh
N00NDXq79hFh6GmL4mw7PApwuQh9Hzx4COJnzc0tzp7JQD56XroPOR+xKb988QJYhcAtPJIQj3u7
t7cXjJTkGt0cuqWlppKfUVWqVp01c+aevXtx8E6YNAnm6Oyce/nywRwdHhqKyzzcy3i5gWRJnZ2d
HZIZEr30dHEO3rsXw8DPDx8/trSy3rBhA0J9oWMnTnXmfDlSsKHPgBWkk60t4DUGDhiQlpKM9xjv
8qbww0YOT0M4HiD6esO6dTfv3IZhonXrVhKVjAwMEo8fwy8bNWyEHbpP377Z0NbM4VuOHQmiZRFE
ae/QbfGSxdhDT6anuQ0ckL23ytek/Pr1C5t4k6YGW7dsfvrsOfLv8Tz5xUURTuAJCQlg9B/+Y0r0
oWRcXOyTx0+GjRghAGzgV3z//p3nyJGxsTG1a9eG1h0KV+hoJEhr2rZtfLwA9xLjdBs0iLjQXb50
CVe8jh1tYmNisNFgXUHtJ6hL17GsYBXkMMFG2peNmzabtG2bmpriP2/eoYMHkJytYOHCVNY5EhoD
Xx6u8wsXzEcKxYMHDmJTkK6IKILnz54TOR8HuQ30HDGiX//++A2VLtgy2RSQelUCLnLrtu1t25pB
l+Ht7R0bHe3i7CSGRSXfvg3enUhKglJt2ZIAeKQgeGuIu7v0AYtQLWz6v3//Tjx+/DPyK5K+ylWq
7N65Az5kM2YjqJPHXNwakoG0AdtylSp9XHsnxB+G0yhitnF6k1Ntw0kRe4oIg8XayvLChfMoEBwc
3NHaGs3Ub1A/KiICz/Wudl1Xr1n7/etX9ZcBNQ0xRg4zueJe9CrYFKfBnwHcj5avWGliavbw4cPg
vcG4WUlv2AqmCkNF/OHD0KstmOdfoGBBPNViYmJsZDke4eSHbQxuZ0RreLG7DRrsNsgt23wi0Y0q
s1Cf5QyvqUAVzOFAKrDiW5u0vXnzJtywoYKysrKUce+V+TrlW7PiD8fBt2xJwCJsBJCcsLAwW5sO
ApKQugZnIaXgHQwcQ4YOQ/4AMtlKlCq1bvXqMxmn9+0Pxe/Pnb/w7u07s7ZtRcdsl862CYcPIzWv
S4+eAGAR1W3e3PiRUNvSvJnR+XPnlq9a3b9/fxGAOdbMjOm+e4L3hoeFtbNoD4coNW/mFI76Wzdv
zVuw4PVrsalJrw69CjaFaRAiPW/+AvP2Fgi3QsZzJH83NFIZSxS+gaDFsGHDCAtK+ukMQIsXkZML
BqzFxi8yeUOjg0vj4CHuuC/IkC9qs2C4YGo6PDlEwHMUrj5m7doh22FkRAT8t42NmyvqS1Y7m7du
gwv/qFGjiNfW6TNn7bp2zX6Qi1cBziEOWDiEDho0qGev3pfFrVkATlq5ctU8f38oz4Gv0Kt3b0Aj
kseD2x80NRuDgubNm79j5y7iT6XLlH75UiBIjx8/hY79/fv3E8aPk9DbA7sakWHjJ0zw8/Mzt7DA
9YS3YKjv+wpLwrwH8DYgq2Pdli5dpnz5CjxVgvwqehVsZasJ6mvgVEGkERoNXRfSIzdo2IBXSUVi
pZ88uWzJEnjqfxAG38HFt61oq5YaBhYHHALJv4ZlpZ25+fARI0WQetl/pT4YZfPNTX/HnWjN2nUQ
6VevXsfFxS2YP4+H+E3xI5H03Lnz8/z8Bg8ZAvdBojair01NhcesVIPlK1TAvR2/xj1/2bJlHu7u
27bvIOyXxNe2rQlu13AO3bp5M2APZY4IeOYhwXvPnDkD71QUePP6zaJFiyZMnOQxdNiCRYs2bt60
asVymcZU/BL7AtT7eK4HBW4wbtHSZ/qMo0eP/aQCtCZrU8OlA/LsO32GUfPmMbExDg4OF8+fGzd2
TKFCBXnKf/mHil4FW75I4OYM+4Rpu3apKSnwQ1i+bCnMIdk8oH5Icji4uU2ZPMVn+vThwz2BmEU0
gm0CSjJ5ywxBPNKuTtN9vOEFMYUPliZWUeHGSXEl5/hiJFbi5oxMHW3N2uHtA0jwVStXQMmk2gSF
/MW5Om3atElTpuANVaFiBaKRpKREQ/m8g+2at+/zxwMZPnjwIBQrDo5Ox44nis6DwoUKz5w5Ezk9
4ViGNwJuZ5LD43KhJ1uxdMnhuLhdu/ecTE/fuHHj5IkT161etW3rFidHR8UwJLjzQ7xhadu5axcU
71CbNzEwgH0O6iHYcaCLVeDjiEMetwys+YWLAhwdnXCcJCYlNW/ePD0tDU8YZydHkZJYsQ8VE6O7
gAjt7esL34O5c+e69u6VH6wSfZTjB0Q1wLnYmGig0qIdoinQrkWrVlCrirVM4q2TkzPucojxxDlD
ZjkeTqPHji1XrvyiBfPl1VVtBVMunVOCQHBNnT5zJsxXs2fPgakC+O2UpyijICRh966dSPEDhRn2
erSGbbpR4yb37t2F+lNmyzChIdACgRnLly8jCsBZODhkf8DCheXKl0cmsMePH4WHhuGqvHfPbnin
LFu2HEF+M2fN7GxrK93g4fj4oe4e3ZycNm0MUjQRhcsSYnz12jW4uN26eRO7EkhU+H+FkYy9Vq3a
ZcqWAbTL379Z7969hxIHfhPAk4DPnFGzZogJbdK4sZFhU5lY9+3atcMxDrQJuaNiBNACyU0/IjKy
bt06CHZHRKXmDvSPHj4Azll6ejqaQkAI9LH4ISMjw8amg4LGAYLl4wu6zZAOJCAwGBYuWqj52FRq
IUcEgcTGxQGXxt3D48njRzJmJxGMoQw8DAsAKutEPvIcktrDFo0fgH8A107JxklNgTuI3iFjmxGF
f3z7Gh4eDsg0ExOToI0bv37+JGjk399oPhS5q6vr0WPHJJAS0TsAHoj1o61/MC/0ONfPr2mTJmgc
/wDI4cDBg/Cfe/bkCUVsj5wUBIKdFXpv6CQAT7N+7RqoNzXZ7Im68BOCOwqogJ+hv0EkJn74+Olj
zVq1FWx12MLhWyp2GxdeDuEAg7fTwQMHkEJE8+HlmhZwKK1bv36kpyeswVs2bYQbn4ypETQUXdpF
7ynpFxn/N7gDd7Dp2KGDNX6+cvVKRMQh/AAADNmNC/uD0QRXLenecYPt2aP7icREvE6hNs/2TeRw
ujnYJyUeB7DhzBkzYA1FWhgEEcGVBRHUAQEBw0eMINYP1U+ZzgULGz3CxzEz83Lwvn0DBw06Eo/n
QjygPqpUpQTYQGUken1jiwbIfwlPnjotZF8wVAUIxtIKlOLzp882b9w4ZPAgoh/YTpEeHT/8T2Ee
n7t37wFlRWxxiLMKMfRd7LoumDcveF8IFRLnwjLiBMEb1cvHd8vmLQcPHYJ1UMkjRVo/Ius3COcA
ruDQoR4E9WrWqNmmjQk2hUKFC+WX2CDwZ2EL4DgutDIFm7ehcDh873E7aFKhsibzBZd8ZFNG5Aky
h2Bbxwps2Lixra0tbgfQrWSXVCa0vJKUFUAwziHOZMniAISF4h4xe/YsxJxvCAyCD5zmgYZ6Emxx
AoGLgz083r55AyceJeYQVaTkQESEpZUVfH2JSsgaUZofvIl493Nnzwi8FKQaBCAe8FR4OhjSviP6
ERTv278/IDIQxId0E4jCV2VEuaUsae0CbwTGAsQqwxIp7cYne8IUxCMiOsrIqBnPVYFf2NKyPeIu
IDN1a9eGcxhPfylLfmLj48E4ydsWMQh++SEeQ4F/gHRfMJoePBQhIbGQNJiyoVhBF0gGeCUzc/78
edB+CYqprt+hxG8uFyGiw4Z6IBcNzGzAhIHvTXNj46nTvKDPP3bs+PXr17Fb4eSDbh+OMdCTA7/p
54+fihvXvWBLeSBJ7GowU8MBuGbNWnAVRLa1bCJSoopc0xcu9tu3boWPvqgZYNxF83Ni82MGmkTF
xEr3AOv/6lUroX2Rp3KEQRUBPRPGjJk6ZfLBg4emT59+6tRpiiPNfcVgpu47YEDp0qV27dhetVpV
qhNUdqZhz92+bRuSb4mWSmJiEnwZ8J9YIZZWlgcjoqT7wuayfNky+CDkzy875BYWuIzTp0eN8Jw0
cWJUVNR8f39AUAvakRoS0Mhg9BZbq8qGTXX6EuVIzRq3MMa6unTxAlywcMJBvwunaReX7s2aNa/f
oCHejw0bNYYFESb9r4QDlT7t2KJxy6ILNIQ9evXq2KkTnIqg+cyeMnUiyimZceYsHtU28HASfpBV
kbgi9mPa1Km7du0WpcjGYoK90bVPH5gloNCQx6QKFcohWujqTV7yR5B++/bt48aNxXagJlNzcjXe
juzax8Sk7cplyyQCaRRNi7wW5azLy5mZWBg2fIdN4nv+4jl8s4mfEWmLxzDu0u/fviUWN3gHM1Jv
V9cRI0dUqCTmcEIeSanSpRE0cvMWLzcbLHC7d++eOnVKdtylqKg8aaFw0dAOPzkcuGDB3xn3haio
yNu3bz158vj2zZt379yGSh/o92lpaeXLlxPbdKQ61v2JLX+uYJ5rH1d4Ys+c7otbkMpEUUjoU6dP
AzWOjAK5ds1qRwd7ohdcGuHwsHnz5qYGhrAcILAW0QV+fnPnzZ/XuVMngOPxFwwJbkX4M2wPLt17
IH6YaAe4dqvXrBk9ZrTAKY023qtMLC1XgFT36de3m6Oj35zZFH31BSMg68zkbMonT52GCwMuqKJB
tzA2xp5L/Cc8xvcBBHzvHkOjZkiaa2dvb2BoNAMunTD/OHQrX45/zMr8gCLeq9f5CxeIPxoYGiCJ
AuwvvBBrPr8lRyjRCPXDRsvEzgcVALS22D2pmw/1JtjwH4ZIww174oTx1PUNYhRTQGguFzEDgH0n
l791+87bN/w9nv9B1Zl8IinhSAKU8NCrwRsZGyF8DwBaWqxoMbGOxB9XNjY2iAcSFcA7EIf8FC9v
GFrVnIi214Gu24NOZIDbQGeX7rj2qA81I599cO2AxZE8C1iGnEg2W2AVwbgN3vn7+0+dOg1+CvAh
gdIbvCMwsOSNqoO1NXB/RS2jHR8fH7iU8Vy79Se3uuCXfgQbOoAh7h49evYcP26sLmaFjDbw1IeT
CfkRsmrVqtSTJ8m/gf4W23+XLp1h1oZXGTESxAYVkggXE2c5rvc3b9zIjtFDmG6P7nXq1AnatFkX
c2Fam/COhAUIr6dpUybzhIFMHG1cWKAiSklObtiA7zss/A5GRI4dP578G9hNCN51sumAkA9iGPAS
h+YMP8DoLJNu1lbt8UA7f15waKMMogNbtW69Zt16yfIUngx6ZI1iEDgMTB+CzeXOnusH5Pepkyep
ShpYFxGJvXLV6iVLl23eshWvYsE9SryhW3fuYuZ1gdtMWnaIuS9VqqTSjRno8/mhfpHYv0lshgnU
3WPo4fgEcp9TJ02Ere7MmeyQIFWnllPKI091terVfL1loO0rpi30uuEHDsIRkOBdfHyCzGDYe/cf
wNm7di0h5jaf8oCp+vTpk1IS/fr9uwCPd3JXNV5Sw4YPjzssiK8mGpwwbiy8X4HDI9Y+eQFIG9iU
DkXHBZRelPQg2BGRUYiJ85s9m2fwVHGP//LtK6oA9x8OdwULFEhLT8czb8CAgZB2ssfvS/6rCV57
PPIKu9gUFNjVzk4pwbP+ZsEiIllM/FxycXKCm4pAecMvikAxPz//yZMnwb1ZaRc5rwBoyCcjXCxx
B57v58d77Kl4d/32/TsIi7yWDRrweAcliLOLMzReCHJE6JKIJkjBhZ9rVK8m+A2/F9uONt5eXrLp
RhoGEirirJZ9mgmXQXdnZ/h7i+Kr0Sa8U6Fegd+4klBqFeerXy7TLdiwAy9dugRPIwGGkYrEwqkL
RwJcfXt0d3F3H4J4L+wRXl5esPW1t7Q8cPAQYZ3++OkT3loCd2JhF1u2bYdHkVJyA2IBnsb8DUEO
VjFfaQlg483iTg4A06hTtx7ckpV2kfMKEFduLnflihXwhVQvMQ0CJOH5jyR43V2yeTd39pw7d+9a
tLeEeIPuPN59/FioUKHsNJfEvvnff8jWopRuf5ERKwuhXULZJnNQeOoicgtoJ5u2bCW3Bvz9NiZt
d+7Zq7SLnFKAbsG+eOky/N2tLMVUIxoSq3nzZsjvsXfvXjgDjxk3HsGeeGuVKVNGolnEAyPQX2lf
cAom4v4UZ9scNXLk+rVrkaqC3CDc0VetXMnTouXG78bNm7dv37btKEQ4oDhHhZcyqKYBORgeHpZw
5MjQYcPxsPr56xdAAiWuAzGHD8+cPUtph+Ad4K7+/MmCsxOvsPSxwf8NXF+3bdmC3MnkBvv367d6
1SoZkV5Ke2VkAboFG9szQvB0ERoFVMrdO7YjlLpPv36QSTiHSRAcCZARVKCUC9jt4f2DYkePHOHF
+sn5YAj18vEeM2Ys+ULewcoSj5/0k6eyK6n41lA6PD0WuHXrdp06dXnBRipNisKlDJrLrZs3NWrc
COYoxMzznL3Eu0AIlGJHYIIsuIfjKQQVCXL3xB2Ol0erevXqzpw9e/y4cQQsIfFZmLcrW7ZMcioP
xzIXfPQKNpeLIw4ZqrVDOCm9JQyqs2fOgMgtXrQIbgsSvUyZPAlZBOR2LWwNkslDFIf/SQtj98GD
EYogr8rokSOhUB0/cZLobQZrPLBWrlwVYk2jJoVlrR1qaKsVaaEV/gYWYCB78frRwaSw1/t4eQGg
H074OHgluujh7LR65UoqU0SAR8GCBY1bthg1YsSWrdtkV+Fwhnm4Y6MfPXYcGRoNBryrZN5R6Y+p
ZegTbFBw+sxZUZGR/fv21Q41pPWW0PLz1wcchn9IOdMiywQ8E+V2TWqNeGPXq1cfoYLz581bsHAR
GYJD1AL6WrY4AMsIztK4/xO/xyvgy5fPgjIqnWzaIYrGrci6vsIYgegI+IS4yYJ/1LRL0ZaaP7/3
1Klw7CM2VvL35OnTM+fFXj0yO4VK/A/vjZ2vQYOGwHhYtnQphi3zdg1rGTAtK1asMNjdQ3Buczjg
neL3l6YzpbE+TYIN5VYnJGc4ejQ0NFQAb0SepFYFoGr1aojTgA5GgoxXr1x5pQwCjnwc4U4OzD3s
RNFRUQgeEORzER8qnIE2BgUC9AfRJog5xT87t2+vUkXoNa2Dk43GtSHoCrgXdg720ZGR+/fvx5NY
+wMgUQnu2QPdBvEsW0I9PHEnP3k6Y9PGTUq7Jus74YAUEx0NuFI0KDMTCFyYgW1oamZmZd1h6TLA
E65BLGDVqpQ93pWORq8F6BBsJBbu0aMnKJhwOA6KLt58JSRZ2wIAPDNkP5c4Zt093Fu3lEQRlya+
xFggtDFRUVCwI1U6ALGl/TEAcwVIemxYv3//WrViBaKFncm4Flrds+hfKnfv3O3evTscbxMS4uGn
RcMA2pqYwDCByFkBqfna+PLlyiFrh9LegWmF/4mKIS99dGQE4kaQTwJZgaRVA3i7eXtNg1YV7y9k
huHhkzo5Ku0lRxTQuWAD/Q8AEYCDXLl8GdImCoiitiRTkxPjZkbo6DWRD1FYxbaDDbBZlHIlPw9C
SYwsSPIE8IBpXl4wdQKzHrZcXkIJfPxZwBsR+tXQ8PCgDYFIwgi47OxpivuiKu2aaQVwiUX+na4O
DuvXrpZA81Q+VAWcUsjEFnwY0xdCVFCCzvAwU5DInjwYwnNDcHRzOLDMAbRj1uzZ8CXv3qMnkEnJ
j2qEfyI4D7xbv26ta9++SCpAdlBXPkcGl9C5YO/as7dS5SpzZ81UJ8xDwXmqcHHAwROhPM8J537h
JjJyzJiIqGj1eAFhB4RAWmoaTq2pk6c0atIEoSOIp7O0tMJTfED//pCBiMgIPNuwC2R3ofb+pd4o
tV1rX8j+goUKzvf3kwm7paQ3leZO4iZcFYAn+/rNa3L78FYAAkH2b+RwH8c14TWYfSfncvE7JH4A
GKCVtTXCwhDtY2pqhgSAHTrY1K/fsI+rK97V+/eHYuPggfZQOzm0TWntt6dbwYa7SFBQEELkVQsA
UjxNgvT8G5q8guBlq1at4BVMLgB9qUTmF5nVsS6APSzTZQ8hx1CtA3YL2Gk4wOHrjlUE3Lkb168t
XhwgQnTQPpdobpEgLJcLaE5fH18FuWxVHpeIdxI1xXcBE9O2r8SzT9+5ew9en0p3TFzECeVZNvuE
LeMoRrjRxQsX4E+KwA8YL2AQrVW79vWrVyHSJibCeCGV9iOV509fBd0K9vXrN3CtRfYjbU5IRHqF
PMCT7C0Rryv8gHnaxbaT0pFgTfC9l0iKAPEdBN6UsITBfWrQwAHIz3zp4sW75IyNSjtgfgE+Ye/d
uw+TMgEmpbVPJsukNmigbkjwrmGD+kgSoHQY8I/L+qPIaxDXRqTycHFxxhk+YeLEu3fuXJefQFtp
d0wuoAPBFu73mPbTZ89aIXZSxE4a7znwPPssMjvxOUB1L+Zw/vwWdx2TqCmaBYfTzNAQULKA0c7m
MY1z1OnCgoXJ2NhYabCBFsYgxZgypUtLmJ3wAho9aqTSvkSbsqJhC7szbNKkWPHiu/fwctnnvk8H
gk0Qjv9vwjcz+/SjKlvy6UxZbEqUKPH9uxgQ/Fw///ijR5WyEOMmrnNyP+EsYOX28/eHM1bwnj2w
CQnKaz5HpUOkpQBhzKe8HVIYk2Lekf5aomSJHz94zn+iDzmoJ0+eorQP3lX8TxY4qDSqEVFDwK6v
W7fugbBwQIgpbTnHFdCBYJNoULZcWQGijWbLHarLmTNnIdyPl5bh5CmxhCkylwuXCyzR7G2FP6Si
RYogBYQiDvGbyl8gP3GdU/zdu3vv9OnT27dtjTh4ABrjA6TwfWVVc8bfceWB5V/zsSJHD8E7QEGD
d4JALmmukVZIoUKFgcVL7vr9h/d37gi3TvljgvJM8IxSOG7k4gDc784d2w+Gh9WoWROxQ5pPk2kt
6Faw69WpAyICcEOFaYtYTuI9Utsi10nlSpU+fPwIjFtzi/Z43MbExmUDX0gZxgn9KLnfwPXrkM9J
0Uj4awuLA3ZUpVfQsAMHgEqFXkqVKTNl6tQtmzchTawK02R80Qb16iL1nOa5wevUqoXAO+BD4nYd
GRlpaW09fvyEyOgYBfGtYIME/c3amo4ZM0ZAM5HvihQNwfJ/cEdV9oUfPDTIzQ3vbYTWT502bcf2
baotUWXtM+HvuhVs2A/KVyh/SaWNX5ZuDD4G9l3tgPaMdALQYQKHuVevnsiZhnC/wKCNvAS3UjcC
5LjHxk8mcWJyCoDgZBOdtC9gccDGg2JZRBZlWR+CT4Gw00bosNHTxRnW7zjkQ5fYXyg/HJiwFCTG
gHSWderWuXyF5Peu1ijhTAZMXyirgJYD28GZjAzAjyKzB6D5YcEih2GImkeAVzboL/+31atVbdVS
ACMtCdtCVCNuWzx7Fwc/SVzWJAZ+IDzMtK0J8UvA4JUsWTIuXm7EiFqT1n8l3Qo25te5cxcyipBW
ZgyrMpDG/P3mAuwKDTp0cwQuh0SOWyT9KF68OLm748eOyYQc5pUh7Qu8lfEPicX/EjFeMr+HDx9V
rVZNZJmHY+lwT08Aa0vuL/rQGmqFwkQjSMShdd5B8mAlQR6MowkJgDFC3AUSqkocmF++fCkmnuE4
LiEBzj+KpkbctvIXwFH/799fIuWLzA9bCXYNESQufhjuOQK5+7IL5+TtWDQLnQt2UwODs2fOaHG1
kU9FPG5HjRyRdPwYZNjO3mHL1q0ij38YscsSIdlCPiGrE/DMcNjCTfLRw0f4C26DCDAGpxGehR+I
QI737z8gN1pIcLDE2iJP4fWbN0ACIf/G3s4OnvBkXA7BX+VZbrVJEV21BQhB+HXoqHX4hAElPzkp
sWzZsg6OjkEbN4mC5LJ5J+zboEnTzEuXBe76xC9liR9sq3///tuxfXuxYrxM2jI/Hu+qi2Ugcuhq
h3sEYMkF5TXTB+mIXKo2q3PBNjI0RCpcbQIGSdEdLyW4hR2JP/z167eu9g4JR3iq78zLlysSOc2F
5YFwMt3XJ+PsWSBgmpmZ4QK/d1+ItZU1wLEDN222srSaOIWnd12/YT38zGEIwZ1cjJqklQSnUwlC
IzrC0Mjo7PnzkgzIoauEP1mksAMmJJAnVV1V1MsjpRZyMB0/egRXJGzNvMwqXC6wIhFXn90Il4sI
6tTUVGBdQQ83cKAb8NI+fviAkxYot4iZx7+RZBMIapcyMx8/evT61WsFiTKQclUCDgBYiMjBfvac
FO+oT4N5JXUu2M2MDDFrsRBl3VABSiy4Fm3buhVp1gEoC8HOBsQj9Yh7IJK33LxxHaf9kEFuKIYd
AXB2+CUcwlEQcZoI5IiLiT525IiYPowkomVKl3ny5ImgVaHAOzk7X7x4STeTo71V/mSRTrxI0SKX
MrWgG1c8geIlS44ZPQphoSeSkxEjfeZMBvIxZVfBYDgcyDb+jYBw286d69apXax4sQ4dOiC9VpOG
DTvzvzKlS9XluxLv2LkTQV3y9GHQ9j988EDiwLez63pRmJCAdlrrpEOdCzbeMB1sbK5cvaaT4Us1
Cn0PcvQYN2+OI7dWLdLiIJUsW748NEP4BXZuuHYDhxDOZGXLIcUHL0sjYrlxXGCp/fj5E4g8Modd
s2Z1BKISGF2iGwF0aXjG0zNNnffC362gRAC0G3I767w7fgfYT5cuWYyMtv/+/qsPMZb4+HsNMkIP
Rsa8Ro3gvo7829DJVatR3Q32iQH9wccKFcpXqlTR0sIcRvjoONlp1apUqYy0ewi9Jjdv0qZ1ghxe
0zN3rfeic8HGiNuYmNAETCE8POEGbNvZlpeyk7oiRHggi8BrodpZt3atTIgFrCp4ht8Wt6y2MG72
6OHDXGI4EVLD2LjF5cvKESC1uC6RKxMmMfWCC4iYTeA0AA5x7erV8iAWYH67dp2XpEn04cH45etX
zW17WqSDhk3RIdjGzZsdSYhXQcbUnpNwOZ47f74lEXqt+IkrS+yhFQfYJap26tSpCTI87Q2WHA7f
jorFcUl8xUPasYVl5hZsHWLWzZs1O3okQXA3UZsvqlS8ePEiNCCq1MguS9ixoRiHLc3C0nL7jp0y
Vx3C9SV4h3UChl65dl29fhlYiw7BbtG8+ccPH+/TFSkBZQ/ZUKmI6LLEnhf0x3dyePzk8eyZM5E/
5LZ0nACHY2ZqeooMWsjvBkk87+P9los+qEhwrb2pi6yDsnZVnLEh+/ZpEjUEWxeUqbBr+Hp7ITpN
pnLHvJ0ZVHESXAJS/YNcxDs6BBtmXviNZdL1zI4/eqxGjZqANJQhX9Ru5tDQom7x4iVg8Jy/YAHy
tomScopuAS1bGMPHGJlZyb3gcU7kKsg1Hx86xvaK6Jkt3+tL5SnL2lWPHk9EUl7QVuXWhBWIZA+1
69RBRpclS5cg4yzPf0n8a9KkCXCOxXLIcLnAP5NhrVR7HPquSIdgY45QZt64Qcs9h8vduWPHgIED
ZROWgvGJn0mCtzhMTEyOHj8ObY2Ts8uIUaOzZVi4O/Tp2zdWPNEPfJgE7zpqO4i+uU+pfzxqst1U
+ApqStXUKrR3zx7YrjTpgnAphQbuWGJiZ1tbtAa4chHUpGhQyEASS8Yn5nCwj8NbUa1RM7ESLYLN
5RoaGiQnJ9NAgOSUVATTkzMzqtEpsTg6WFnt2rkTDi3wYwXMsGvffgj8EJ3YWHxO3boFBQYCXkfU
BYAlJNKPqNE706oYGhgkHteetl/+lnc6IwPp+BwdHNSmAJQfxIndycYGHuDI3DDCczjyB/bs3Uvi
PeXk4LB1y2ZyNBF2c21CSqg9By1VpEWw+XHL8Bwiw01pafySzezctWuIuzvgdVRuX3jJxD0c4QpQ
FwHGsHGTppF8NCWAwAweMsTJySlkfyjWDtE4MHwQ/b9l63ZRX9euXxd4xeBX5BWckw/w5kaG9+/d
l5n8UGUio4L8Ax9ZfvoNGACDpcrNCskL3v38+QPyjDw+5uYWCPZAU9iXx4wdB99VhNkSGaDwwYO9
R89egZuykU+vXbsu5hWj8iAYVgEbFfkfAPpXqVz5b9Yfid9r/p/INY9DW/N2FLQAjQgGf/36NU16
gXcEwshWrFyBRu7fu4cL+bOnT4kGb928AYOpo6MjMjNn/fmN37x/+wYFNgQGXrt2deOmTTWqV8/M
vKxJ7/LqLl22zMfXV+2W375+DcoAMES9FqytrTFl9epSrAVUM4wQty1B+X9/KVYkF7uSmYlGFgUE
4JfPnjxp06YNHEWJApi7u4dHF7sucYfjCN59/vjB3Lzd6jVrwLtt27fDRxhjUKNTvVQBuDKAGRV0
TcuJzd/LbHQQUZC9SfLexf+WLVvmMWwYVCOabJ7Y9c3Mzbdu3gL3Rpwefn5+4ydMINyY4RexZ8/u
SZMm7dyx08SkLZAbDkREwrIyz8+vU8dO+5FHd98+JG3WpHdm1gVqOg40nY5t5cqV/QcOBOaUoBe1
XvJQ4Ju0bRsaEoIQa8DLL168eNz48YT7IM5wJNmcMX3G/pD9LVu1nj1n7v7wcMT/BixcCN7BYXHX
7t04e3Q6Rzobp0+wYQq6nCl0ddD61ZTDiY6NxWk5ytOTLO1qkBLaVAQ/bN6yxWvaNLgf29l1AWjh
+EmTgKNMtNahg/XevXt27d718uULIOzh7r146VJA5MHtzMLCXHaPWp+vGhPToAoeJefO6jD1NwBS
0lJTx1AAP1I8iZ+/fwHrbuu2rTOmT3/44CE4hXfZyNFjRG9AmLd37Ni+PyQE+SSiIqPgXhqweHF0
TExK8gkU1oBCjKtKl2BzuU2aNEaaO0EmSrX2YxnEEwoMODdr5qzpM2bAwTC7mKq98FuD3xJcKc3M
TId5eoLr+A1cFy0s2rsNcX/+9JmocQMDAwAPw5oCxHm4NBoDDVtBd6qOhGHrBHkUEcmjo0yU2DFn
zZo1zdsLqfk0nPevn7+QeRtOgRMmTPCfPx+tIWkvnk4D3AYhOETUOLQnDRo0GDlypI+3F4L8W7Vq
yXNSzF0fXfPhcIyaNv3x/cf1G2KufJoSUygwq9etB5b4EDc3jRrkt4Yo/4IFC+CHUZ7DMzIyjh7l
KYQRgQTMDScX55QUgWMDbv4nTiSZCeP1NeqX8ZWbNmkMv53LuokG2bBxU4kSxYcPHcojg2ZXG/AO
zqRoBtF+eFRHx8Ti5759+2D/BQg8OXdqUlKSuZn8DI2M54jSAdIl2PnywR+oRauWVzRG5JCeEmQP
2GNLlixGLIfSCSstgBj9//7jpeBFHm88sP385hIGLWDWBgVtXLBgAZL7paenr9sQiNw38L1R2mAu
KAAbHlQJWo4G4ctwSmoqsnCsWb1GYGrS7GqDxEBEOxiwnz9YN4cwaNnbd4V6DOmvp3l5p6ambdy0
2camA8IBcwFr5E2BPsHGCNq3t9R6/CYc9ydOmLB8xQrkx1acRYAiF0W5taNiYrCUy5evsD8snKgL
5UpcbAxSEbi5ud24cQNJdjU/ZCiOSu/FWrdpw0Pz1OxEFZsFhwOIi/HjxgcELNZWrj/wTgSP0cHa
ukXLVnv2hRCd4q0UGXEIb2x39yGnTp4cMXxY7uYdrYLdtGmTI1oFl4KyevSYsch0D/h+waLRbMtH
I1+wOIry8Dc8hw+rWKHC8+fPfby8gZ0YsBhIm8u9vH2QJgadrlqxHAGevE417lHvQktlAAYGTaEp
FMD6akO88WJH2Ly9gwOuylQGQKXM5y9fivJ5R3xjRo2CwWL8hIlgHXjn7Tt9uo8vHNGCNqwXJC3K
vbyjRbCF68DIwBChsAQskeYfUFmmevuAkd7TpmremqiFV69fwzMU/wkVGh7WMGsj5xPgexrUr1+r
Vi17e/vTJ9OnTpnM8zDLvctC+jRrbmT06ePHW7dui+1l6kk4l4tgWLxovn77OtPXR4u8g1s48ORF
g4fxzLl7d6i+69erB+QGuy5dUlOSERwC2BYtdsrMpmgRbKEA1KlTG3ijl69kqkkL0jKCdh0bcMap
U6tWruA9q9RbYbLGAd/DcqKsoPwCnp6ehw4ccHJ0cO3dC/hK2W8z7XWqJkF0Wk20bfGnidxXdevV
lQxKVWNr4/KAImfMmn306JHA9et5SgrtkfHhw4fly5cnbz39+/cLDw0Fqpmra2/wjpcIlRiz9jrV
KRPUbpwWwRaNDvlQ7eyuqh3mRVpGJ5JTkhIT94XsE3iPqrHCZNKMy0WwChzIyH+0smxfshQQao8I
filaE9rqVG3u0VNROM2OnWy1AJjB4Zw6nYGU9CEhITVr1RI7/zWeDrQA1cgZM7lcRIAC0kyATksW
5tzOO3oFO18+RBQcP6Y8z44MFotvsZ062uBKzFOYafV7+vTp71+/JTGVOJwh7h5YiIKucvuakEdR
8E4s5aW6lIcbz9kzGXAEULcB2fUQwvX2zRsku89+IvE5hVC/HTt2CHaQ3H5Qi0hDt2A3a9bs+rXr
6kQUSIgThwOMK+2uDLR2+85dBHJJm83sOtumJicDoljrPeagBoGEAxsEPLo0H7N2zIQiKeX/cPPO
bSDeiADDRYPs0qnjtatXMzP5D8A8synTLdiGBk2Llyhxnqlonjdv3TKR5XOClCadgRx+PFHzNZ1z
W4C3FrQPFy9fYsoURFLK/wEwL8DzkB4b3tVQoR1PzFu8o1uwcRgC+JJmfDzqCxGAW00ay44hQYRT
bGwM9aZyX0n4XTp063bpEq3YhtTJiPc/nPxllrcwNz94gJTrg3qjObYkXYJNetu0MDZOSjyuBbWk
tt9LsJ8BuA/QxTK52aZ1q4vnL5DdxXMs09UfeHNjY608s8VGoA0+wkoSGxPTvHkzObxrfe/uXQFO
hvqzz0k16RJs0tumefPmVzKvvHmjSgpOmSTV9nsJSUKqVatWu05tmb0hwglg9BcJZFJtrMWctEyE
Y8UzG9EU2vJEELSqDT4C7h8eDY0bNZJJVYTfVq1WFXlCBH/NA+yjS7BJ9G5maFC0WNHzFy4ybWWf
Pp0BeDO5o+JwOtl2unHzJq+ANtYi06ZPZTzY3UqXKcNLmsEw2Th56nT3Hj0UBGnZdOyEHA9a3Eqo
kEuPZfQg2MCCR37My6LtU+3Za3VtATQHifjaW1goGE79+g1oA1FWmyo6rQjJQSYjHu8YtbVxuaH7
QxTzrm7dureITVmry0an1NakcT0INoYLzBreU03cXKHyNLS6trDlYwBtTdooGAbQc3SKN6AyBfRR
oXXr1jHRUYwSj3PnLyBHqoV5OwX0qFmjBnCX9EEw/fRJo2CTdso2rVoho+IzEW6BVkVUPUICAmWw
u7so5bXMRniw4S9eqNd+rqll0rr10ydPoYpizozAO4+hQwX4sHKGBdjwDx8+8CJwGbDYaCAdjYJN
8tEFhEWVKlXOnD9HwwypdAEIJKR6dHFyUly4bNkyQNXSaVpZKqPVb5latWsBP+wcY04/OJwBzMzZ
sZtispQrWxYFPnz4qF/q0dY7jYJNzEko3o7OzucZk5E4NDy8T99+WLKK6V6CD6vw588f2tjDzI6g
IgGaLSPGhtc14nOcXYAzqYx3vKivrD/8BKl54JlNu2ALxbt1q1aRkREijG49rpLXr14BwwPgR0rH
ULBgQZRB5jelJXN3AYCERUVGysxDSvPEP374sGrlSvchfMQLhV/hwjx0HU5+fmhXHriN622NtjM1
ff/ufaYOkJKUcFhqt14fGNR/wEAeaDG1jRzpdZWtolz+dzMTkx/fv5+7qH+DJRD/nV1cgF6olOIE
REThQnmFd3oTbKRiQBrks+d0CGorm9ni4bh3bt+JjowcN2Y0lY38589fOK6L5IEwfSXX2lKl7Ozt
z+n7JfX0yZN9wcETx49XKtUo8OPnT/y7eIk8gVHHu1dSIYqOyiDwPZUA/aR2VGpzGMLLWIOGDU6m
p1WoWJFK458+fy6KkLI8cJFTSg0rK0vgqCstptMC1WvUANIGXMqo9PLp02dsyrkpO5fiWetTsJFi
GouDl8VSr6JCHSjn/fv3hP6M/czNzDJOn9a78Y966O7b9+94m3Ke+fQp2AZNm1apWiVVKn08Y4kP
wDatIBwzdoLUBwZw/yZNm6TlHN69fPGysDbQqamTSL8l9SnYOKh793Y9fZrn8pUjvsdPHgM3P0cM
lYZBwsh06tQpGjrSShfgnVbaySmN6FWw8+UzMzM7EB6OnLWMppdQBXD50mWAEzN6qDQOzrydWcSh
g4h1pbFP9bu6fv0GQFEF9enX6ag/cDVr6luwTdsWyJ8/4wztunGVyMU/pZFT4mR6+qdPn5hge1dp
+Doq3KplSyD7Ej72DP8QrQ0IAKDZCTLd54Frl54FG09WwP2npaUxfGVgeOcuXIQ/6b9//16/fs38
0dIwQkR69e3XP5WxvCOFGCHO9Ps3Xq6fl69e68EEQwMzpLrQs2BjPDCchIWFMp/cMLl36doVzmcv
Xr7SB6eY2Kdl+/b79+2T8ZJiwl2XhIh25uy5DjY2QAF4+fqVfk0wtHFR/4INFzTsprzYfSZ/XG7I
vpAB/fsjr/rrN+yJLWAV4KL+++8/iI3kvsywu254WFjffv3aW1pl37aYsPXocsHrW7C5XJyBffv3
RwIA3jSZSm6sXfgkdrC2MjA0fPPmrS45kpPaxm0cL6nklBSxY5BhTATw8Lt3b7vYdgIKfTbvGLb1
aJ3r+hZs0JfDQWJE+AbypFqC3AxZIlwuIn5HjByJaO3KlSt//PhR62zIuQ3adLBGxKvgNk7wi2Ey
Ext3eOSo0YjWBu+g+8wmNUNWl254r2/B5s+qnZnpv39/z50/LzlHZiyRd2/fhezb18OZF62NsN7P
n0mLQzdcyUGtIkoPOQx5unHpfZkB0/jy6dOunTt7uDhjLMisKCbYDBie7obACMHOX6CA26DBSSeS
Zc+Tnp1Vfi+I1nb38ODlc+NykX457wTrU1p2HA54dyL5BNMOamLwYQcP4XWNfA/4mce79++zJ8WM
Y4MSkVUvxAjBxrC7dum8e9dO2Z4q9DBATi/Y8gMDNwzo15e4ZMI+9/Wr0M9BdXLnyhp2nTvv2b2H
gZ4qP759W7N69cD+/QmyFypY8EOeeUYxRbCBgNGwYaOUVMYZtLfv2g1wFQQSEYsDTwZYs3OlfKo9
KSDPILdO4okTarego4q7g/c5OjkByEnIu395h3dMEWyQvmevnkeOqpWIU0frIl8+RPxuDAwc6j5E
1MPPnz+LFCmisw5zasOOjo4JCcI0w8yYBCLPVq9cOXyoh8jUgpDsYsVyf8p7gvwMEmw7W1v4jX9m
0mVp5eo1Y8ePJ15oxIewXjZyU1pyO3e0ORwX9wY+efQoRCjsHes2BA7z9OSl4BY+sj5/+lSqVGkK
VXNDEb0KtvgigHYKeo44xmz8CUeOXjh/3kMcTwseDhUrVcoNnNfqHIqXLDl4yJDYw/EMUaElJ6ck
Hj82cvgw8ixfvX4Ni5dW583cxvQq2CJ9lVDCnZ2cgvfuZQK13r996+3ltXDhwv/973+C8fAH+fDh
w+rVqzNhhEwbg7OT404iv7y+P1z6pk6dsmDhQgkYhsePHyM3G3PuFDqlk14FWzQzoYQD/hL4NfpP
1Mrl+i9YOGjwYDMz0+wjiD/I1JTkJo2VIN3qlGGMbRywGRAbJkTXL1y8pEfPnvB6kqBVWmoqL2sf
PUYWffOJGYJNosJAN7fYuLjsX+jjzbZ9x86HDx6MGzNKgjvIw5qV9Rfqe31zjZH9czh9+vaNiSXx
js5hCtfJvpCQC+fPTZJCOEROiLdv3xgZNqVzUHrsi3GC7WDX5UBYWLYKjeb9lctNOnFixYrlQKsu
VFh4CRfy58y5sz179YI7jR4ZxtyuuVz4Y8cf5qvQaPgkdnz+Ojl58tR8/3nr162XxrE7c/Zs9x49
pXlKw0j10gXjBBvvon4DBkREReuFHLdv3x49anTQxo21ZWUFSU1Na9dOUeY3vYyZKZ1yOPDHHjR4
yMGISDqGJLXjP7h/33P48DVr1wJ5Vvohjbhxc4VZ++gYM419ME6wMfduDvabNm2kH6jk1cuXQ9zd
58ydaw7plVo3L54/T0pMtLG2opE7Oa8rR/AuKIj+JCFQdg4bPnyqlxcwrXlUE2cf/hoTHW3bgf+n
vPExUbCRlKNGzVqJSSd4LKDrjY3cbjhtkBKkbx9XmayPiIzC+/8/1jtFoWAAvbRVmzYJR2mFHIfb
r8ew4V3tHQR5mqTWTGR0TG9X1+KlSuYNoebNkomCjWF1tbOLjomR3np1xJivnz4PHznS3MJiLJES
ROpDhs11a9c6KUvpqKPh5axmO3bseCjiEG1jhkP4qDFjESc/dcpkwUkgflzDiX3tmjWwxtE2JCZ0
xFDBbmdmFrZ//0dRLI4uz23eWe3hUa9evRm+PvJYsntvcHsrSyMjI9puEExYHOqNwcLM7HBsHD25
BKBk9Rw1umy5cn6zZwlGK/WG2hO8r1GTJm3atBGbji5XlHp0024thgp2/Qb1kbrlZMYZedzSiAri
TJ3m42NoaLhowXxe1ntZ/L5/797SpUuGDxtO2w1Co9npu3K16tUQ0nMqI4MGQZo11w/G82VLFheU
kynx2ZOniwMCxo4dI0kVmq0ttDOFoYINOlhaWkFHTQNBAhYu8PebK0jxIcVv6PD8581HyDGcZ2gY
TI7sQsryZG5ufusWiXc6w2DAJStg0UJo4+XRbdGSxd27d+dpQ0Vfbj+riYkyT7CFdK9ardrz58+1
v9ClFpli329cwq9evTJl4gTtjyTXtCi1G4J3z549zZ6fzo5HxbwLDQtPPnHCa+pUMUrrbDCM4ifz
BFtI91KlSr5580b7xFKFr48fPfKbO2fx4iUlS5fW/khyR4uyDsASJUq8eP5Cn/PjcmG8nDVz5uIl
S5GwWZ8j0VPfzBNsISE4nPz//v7VE1kE3SJsc8BAN4FpVL9DYWzvsjbK/BzOP9puvDI74nBWr13n
5Oxs39WOsZTT6cCYK9hAICoHmDFdfNTWXEpKavzhw5MnUMqrroth5tw2v377VrFiBZrGL2tnOXPm
bFho6DTCAJYnP+YKNh7YeKrphCkUbuPQmQUEBMycNat02bI6GUOubhT5hqtXF4BJ0TpR4Za9fPly
3+nTeS9waps4rYOkpTPmCnZ6Wmr9+vVpIYKMTqJiYn///t3Xtbe+BpCT+pUSnjMZGXTzjgRpDpAm
qO4G9u/HoyGFTTwnkZryWBkq2AAbQ4xkm5b6sTDhbY/oLh8fH55lm/2UUkBceODwc/nSpVYtWmTX
o/PY5HLXrF3j4ztdgQ1M6YRyQQGGCnZqerqVtXW1GvrBKjkcnwC9bicinID9KFJAKL3JaWnNjY15
IVZ0fsLN5Xhi0s8fP+ztugg6p3NPoXO+yvpiqGCHhYU787M36OHjctevXz9m7FjeLS6vLgt1yC4U
rZiYmN69hU8Y0g1ZnTZVr7Np06YJEydmx8yzV3HVaairGjdu3Lh86aJjV3tddaCw3eSU1F+/fgIz
IC+/0NSmPIKigSLoLIqWoVeuMjLOPHr0yKFrV7XHn2sqMvHEDj9wYLjnCH0F2R2KiPAcMTLPKl00
XNlhBw4OHuJetrx+fELAu5GjRmVrRvLwhYtxgo2ooG1bt7r26qnhClOv+sMHDxPi4x3t2S1fFfoJ
5efDu3cbgwL76MmUAFSzgwcOELkTBR+99wVVSKbzsowT7OCQ/UipU7eeIC2L9gmgcBePjI4eOmxY
0eLFtd9vLm5RKD/B+0O7OTo1bdJEL3ONiokBtjnr/EsQn1mCjeN67ZrVbgMG6HBlyFeJZf35s33b
tjzrhKghzQE/BBvhIDc3vbxi4FC0Y/t2uy5CZbiGk8n51fUq2FKH567de1xd+xgYGuiWsHJuaFCb
wa2iadO8glCrXSIjA15Xe3t9BbeePH26ZMkS+updu5TUSmt6FWzxTCBwSgkKChw2dKhWJqZGI/EJ
Cb1Edho16ufhKq9fvVqzepXnMLGUOnTSA95mwKujs0eG96VXwRad2HwJ37JtOxSqdDs2CPkDkJ0D
4WG2NqxTijordvvOXa59+hoaGapTWeM6gD0L3runc8eOGreUexrQq2CTTuxrV6/t3LFdIgMenWQ+
lnSiWzfHvBm7qyGd7965GxS4YZiHh4btqF09KSXVwqJ91eq6CRlSe1h6rahXwRbNnMNZt2HDxEmT
a9SsKUkNukyRx44dsyFv+XT1q1fua6fzwKCgUaNGi/LLa6dRKq0IeZSYmIjnPZUaeacMIwT7xIlk
xHINFU9YK+ABLaZIxC0cjou1sbLMZjwt/eaCdYYsfLGxscM83PUwFz6PAB2NNxSbyEGC/rIFm0Pj
sv7z+9fcuXOmz5iJHMt6WBz8LpNSUhwdnXK3CZSrgzvI36ysefPnI/JZX65m4N2JtDQrK+sKFSvq
a/Hos1/5PJUt2LpYBPLmv3P33mLFi+vL1YwYVUpysqUVg3P3aEMmtbNZEyMR/jtkf+j3b98H9O2j
x8WdmpJia2urxwHos2v5B7Cer+LPnz5btHDBrFmz9JjCEvrwqKhISwtzfXJIcd9av0CpvVMQI+H/
++2bt/7+/nPnzpWH6U0DPX9+/x4eHmbZ3oKGvnJWFzIEm87jetXatQPdBpm2batHqiWnpbe3tFIM
ZKvH4emka7V3CtKOsGb9ehcXFyuyYkInY1XUaGr6SQMDw2ydq9obFu0j13WHMgRbO3c2CgM/dux4
bHT0uNGy02VRaEDdIiL2839IS0uzySnmazUWrhpVFNBVuCOkpaXvCw6eIJVfnuYI9rT0dHsHh+zx
qr1hqbuUGFtPb1dxpLnz8fH2mzevPG1wliImiNjP4SBjG3Sq7c0ZfA8XDpt3k1Jj4fKraPcWBogS
b28vXMKRhklyZasxQnWFA6q78NBQ83Zm2Q1odxdTd2BMqMfhcv/xdlkhP86fv+DYrVvgxo2Ahtbp
+M6cPXvq5MnxE8Zz8um2I8WzuHvv7u6du/z8/cWKMQ875cjRI8WLl4A+Qj2mwJ5n1KzZwoCAcmqD
rpJocvHSpYT4w17ePrpeJIon++Dhw42BgYsWB+h3CanHEQ1rzZgxfcHCRY7dSLcV8Rb5gk36MjMz
PT1HaNgrleo4Q/Dlz6+3KwMxyKysP9x/3EJSKd3y5+f8+8fXAOvpA3HIbyKMx9mlu7fXNPWGg7yl
dvaCRSDRshoNYjB///6j7ckmb4TyeKfGjHJilXnz5tkSOD+yPknBzokzZMfMUoClgAQF9Hxgsvxg
KcBSQBcUYAVbF1Rl22QpoGcKsIKtZwaw3bMU0AUFWMHWBVXZNlkK6JkCrGDrmQFs9ywFdEEBVrB1
QVW2TZYCeqYAK9h6ZgDbPUsBXVDg/1XgHOfEDBX9AAAAAElFTkSuQmCC

------=_NextPart_01D92EA1.A6713670
Content-Location: file:///C:/680A9711/UA164680101_3D71.files/image002.jpg
Content-Transfer-Encoding: base64
Content-Type: image/jpeg
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------=_NextPart_01D92EA1.A6713670
Content-Location: file:///C:/680A9711/UA164680101_3D71.files/filelist.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml; charset="utf-8"

<xml xmlns:o=3D"urn:schemas-microsoft-com:office:office">
 <o:MainFile HRef=3D"../UA164680101_3D71.htm"/>
 <o:File HRef=3D"preview.wmf"/>
 <o:File HRef=3D"item0001.xml"/>
 <o:File HRef=3D"props002.xml"/>
 <o:File HRef=3D"themedata.thmx"/>
 <o:File HRef=3D"colorschememapping.xml"/>
 <o:File HRef=3D"image001.png"/>
 <o:File HRef=3D"image002.jpg"/>
 <o:File HRef=3D"filelist.xml"/>
</xml>
------=_NextPart_01D92EA1.A6713670--
